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Abbreviations 
 
ADME/Tox  absorption, distribution, metabolism, excretion, and toxicity 
Akt/PKB  protein kinase B  
ALL   acute lymphoblastic leukemia 
AML   acute myeloid leukemia  
APL   acute promyelocytic leukemia 
ASXL1   additional sex combs like transcriptional regulator 1 
ATRA   all-trans retinoic acid 
ATP   adenosine triphosphate 
aUPD   acquired uniparental disomy 
B-CLL   B-cell chronic lymphocytic leukemia 
BCL-2   B-cell CLL/lymphoma 2 
BH3   BCL-2 homology 3 
BMPR 1A  bone morphogenetic protein receptor 1A 
BRASIL  biopanning and rapid analysis of selective interactive ligands 
CAR cells  CXCL12-abundant reticular cells 
cDNA   complementary DNA 
C/EBPA   CCAAT/enhancer binding protein alfa 
CLL   chronic lymphocytic leukemia 
CLL-1   C-type lectin-like molecule-1 
CML   chronic myeloid leukemia 
CMP   common myeloid progenitor 
CNV   copy number variations 
CR   complete remission 
CREB   cAMP response element-binding protein 
CREBBP  CREB binding protein 
CSC   cancer stem cell  
CTLA-4   cytotoxic T lymphocyte-associated antigen 4   
CXCL12  C-X-C motif chemokine 12  
CXCR4   C-X-C chemokine receptor 4 
DNA   deoxyribonucleic acid 
ssDNA   signal stranded DNA 
DNMT3A   DNA methyltransferase 3 alpha 
ECM   extracellular matrix 
EGF   epidermal growth factor 
EGFR   EGF receptor 
EP300   E1A binding protein p300 
G-CSF   granulocyte colony-stimulating factor 
GM-CSF   granulocyte-macrophage colony-stimulating factor 
GMP   granulocyte-macrophage progenitor   
FLT3   Fms-like tyrosine kinase 3 
FLT3L   FLT3 ligand 
FOXO    Forkhead transcription factor 
HIF    hypoxia-inducible factor 
HSC   hematopoietic stem cell 
IDH1   isocitrate dehydrogenase 1 
IDH2   isocitrate dehydrogenase 2 
IFN-   interferon alpha 
IFN-   interferon gamma 
IGF-1   Insulin-like growth factor 1 
IGFBP2  insulin-like growth factor binding protein 2 
IL    interleukin  
IL1RAP   interleukin-1 receptor accessory protein 
JAK    Janus kinase 
JmjC   Jumonji C 
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LIF   leukemia inhibitory factor     
LSC    leukemia stem cell  
M-CSF    macrophage colony-stimulating factor 
MDS   myelodysplastic syndrome 
MEP   megakaryocyte-erythroid progenitor 
miRNA   microRNA 
MLL   myeloid-lymphoid or mixed lineage leukemia 
MLP   multilymphoid progenitor 
MMP    matrix metalloproteinase 
MOZ   monocytic leukemia zinc finger 
MPP   multipotent progenitor cell  
MSC   mesenchymal stem cell 
NF-kB    nuclear factor kappa B 
NOD   non-obese diabetic 
NPM1   nucleophosmin 1 
NUP98   nucleoporin 98kDA 
PDGF-B   platelet derived growth factor B 
PD-1   programmed death 1 
PD-L1   PD-ligand 1 
PGF   placental growth factor 
PI3K   phosphatidylinositol-3 kinase 
PKC-   protein kinase C alpha 
PML   promyelocytic leukemia gene  
PO2   partial pressure of oxygen 
PR-3   human leukocyte proteinase-3 
PTH1R   parathyroid hormone receptor 
RAGE   receptor for advanced glycation end products 
RAPID   RNAi-assisted protein target identification 
RARA   retinoic acid receptor-alpha 
R-2HG   R-2-hydroxyglutarate 
RBC   red blood cell 
RNA   ribonucleic acid 
RNAi   RNA interference 
ROS   reactive oxygen species 
TGF-   transforming growth factor beta 
TNF-   tumor necrosis factor alpha 
Treg   regulatory T cell 
RUNX1   runt-related transcription factor 1 
RUNX1T1  runt-related transcription factor 1; translocated to 1 
SCF   stem cell factor 
SCID   severe combined immunodeficiency 
siRNA   short interfering RNA 
STAT   signal transducers and activators of transcription 
SDF-1   stromal cell-derived factor 1 
TET2   ten-eleven-translocation oncogene family member 2 
TIF2   transcriptional mediators/intermediary factor 2 
TIM-3   T-cell immunoglobulin and mucin domain 3 
TIMP   tissue inhibitor of metalloproteinase 
TU   transducing unit    
VCAM-1  vascular cell adhesion molecule 1 
VEGF   vascular endothelial growth factor 
VEGFR   vascular endothelial growth factor receptor 
WBC   white blood cell  
WT1   Wilms tumor 
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Abstract 
 
Acute myeloid leukemia (AML), although rare, is highly malignant neoplasms that account for a 
majority of leukemia-associated deaths. AML results from an over-growth of immature myeloid cells 
in the bone marrow. These cells are functionally abnormal and interfere with the production of 
normal hematopoietic cells. Despite apparent phenotypic uniformity, AML is a heterogeneous group 
of myeloid malignancies, in which multiple genetic and epigenetic aberrations accumulate in 
hematopoietic stem or progenitor cells leading to disturbed cellular growth, proliferation, and 
differentiation. The nature and number of these AML-associated molecular abnormalities can vary 
widely among patients. Accordingly, the survival rate also fluctuates greatly, with an average ~25% 
overall survival rate.  
 
Chemotherapy is currently the mainstay treatment option for the patient with AML. However, 
although required to induce initial remission, chemotherapy contributes to new mutations and clonal 
evolution, which often leads to disease relapse. Consequently, targeted therapies are urgently 
needed to eradicate AML cells. 
 
One of the major challenges in clinical oncology today is that therapeutic agents cannot be 
selectively delivered to tumor site without causing toxicity to rest of the body.! In addition, tumor 
microenvironment has a key role in mediating drug efficacy and resistance, which hampers the 
discovery of clinically relevant drugs. Therefore, functional screening platforms that can identify 
cancer-specific targets as well as assess the therapeutic relevance of drug candidates within the 
appropriate disease microenvironment are fundamental in identification of novel targets and 
therapeutic agents with better attributes than conventional chemotherapy drugs. 
 
In our studies, we have used two discovery approaches: (i) a phage display technology that 
allows the identification of ligands binding to physiologically relevant targets, and (ii) a novel ex 
vivo screening assay, which allows identification of candidate drugs against leukemia that are 
effective in the presence of human blood and bone marrow components.  
 
Specifically, our studies have elucidated the function of the leukemia invadosome – a 
supramolecular complex containing certain 2 integrins and matrix metalloproteinases – in the 
context of extramedullary leukemia. We show that this complex is essential for extravasation of 
leukemia cells as well as for leukemia cell growth, and that blocking the function of this complex 
possesses potent anti-leukemia and anti-invasion effects. 
 
We also demonstrate new roles for neuropilin-1 and interleukin-11 receptors in the pathogenesis 
of leukemia. We show that these membrane-associated proteins are highly expressed in 
leukemia cell lines as well as in bone marrow samples from leukemia patients. In addition, we 
show that the ligands binding to these receptors can be utilized in targeted drug delivery. 
 
Finally, we developed a new functional ex vivo screening assay to identify candidate anti-
leukemia agents in the presence of human blood or bone marrow under hypoxic conditions. 
Under these conditions, leukemic cells deplete oxygen faster than normal cells causing a shift in 
the hemoglobin oxygenation state. This shift, detected by measuring the optical density at 600 nm 
(OD600) after an appropriate incubation time, directly correlates with leukemic cell counts. Thereby, 
the oxygenation state of native hemoglobin serves as a reliable and reproducible “built-in” 
indicator of leukemia cell growth and/or viability. Our study showed that this assay is highly 
amenable for high-throughput screening against leukemia. Our results support the idea that this 
new methodology could be a tool for the prediction of drug efficacy and/or response in leukemia 
patients.  
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Review of the literature 
 
1. The composition of bone marrow 
 
Bone marrow, a hematopoietic organ that is a 
main site for hematopoiesis, is located within 
the boundaries of bones. Bone marrow is 
responsible for maintaining the numbers of 
different hematopoietic cells in the peripheral 
blood at a constant level throughout the 
lifetime of an individual. In effect, 
approximately one trillion (1012) cells are 
produced in adult human bone marrow daily, 
making it one of the most highly regenerative 
tissues of the human body (Doulatov S, et al. 
2012). In brief, hematopoiesis is the 
accumulative result of intricately regulated 
signaling pathways, which are mediated by 
soluble factors (cytokines, chemokines, 
growth factors, and hormones) and their 
corresponding receptors, adhesion molecules, 
as well as oxygen and nutrient availability.  
 
1.1. Components  
 
The components of the bone marrow can be 
broadly separated into hematopoietic cells 
and bone marrow stroma consisting of 
mesenchymal-derived cells and extracellular 
matrix. 
 
1.1.1. Hematopoietic cells 
 
Bone marrow contains a broad range of 
morphologically different cells that belong to 
distinctive blood lineages and stages of 
differentiation (Doulatov S, et al. 2012) 
(Figure 1). The major classes of stem and 
progenitor cells are characterized by cell 
surface markers, which categorize each cell 
lineage and differentiation stage with a 
specific phenotype. The most commonly 
used cell surface markers for human 
hematopoietic stem cells (HSCs) are CD34+, 
CD38- (Bhatia M, et al. 1997), CD90+ (Thy1), 
CD45RA- (protein tyrosine phosphatase 
receptor C or PTPRC), and CD71- (TfR1) 
(Mayani H and Lansdrop PM. 1994; Majeti R, 
et al. 2007) with the simultaneous exclusion 
of mature lineage markers (such as CD2, 
CD3, CD14, CD16, CD19, CD24, CD56, 
CD66b, and GlyA), collectively referred to as 
Lin- markers. In addition, the expression 
CD49f (integrin α6) is crucial for the HSC 
activity and multipotent progenitor cells 
(MPPs) can be identified by the loss of this 
marker (Laurenti E and Dick JE. 2012). The 
MPPs give rise to myelo-erythroid progenitor 
populations, which are common myeloid 
progenitors (CMPs), granulocyte-
macrophage progenitors (GMPs), and 
megakaryocyte-erythroid progenitors (MEPs), 
as well as to the population of immature 
multilymphoid progenitors (MLPs) (Doulatov 
S, et al. 2012). Recent evidence supports the 
existence of, a “myeloid-based” model, in 
which lymphoid and myeloid fates remain 
linked, instead of diverging early in 
differentiation as described by the “classical” 
model (Kawamoto H, et al. 2010). According 
to the “myeloid-based” model, the MLP may 
give rise to all lymphoid lineages, but may 
also differentiate to certain myeloid lineages. 
Ultimately, lineage determining cell surface 
markers (Lin+) distinguish all fully 
differentiated populations (B-cell, T-cell, 
natural killer cell, dendritic cell, monocyte, 
granulocyte, megakaryocyte, and 
erythrocyte) from each other (Doulatov S, et 
al. 2012).  
 
HSCs have the capability to differentiate into 
all myeloid and lymphoid cell lineages and 
completely reproduce the entire 
hematopoietic and immune system. Notably, 
HSCs are self-renewing and are therefore 
able to maintain the stem cell pools. In effect, 
transplantation of a single purified HSC to a 
lethally irradiated mouse can successfully 
reconstitute the whole hematopoietic system 
for long-term (Osawa M, et al. 1996; Wagers 
AJ, et al. 2002; Matsuzaki Y, et al. 2004; Kiel 
MJ, et al. 2005). In principle, when HSCs 
divide, one daughter cell remains as a HSC 
with the self-renewal capability, while the 
other one becomes a progenitor cell that can 
no longer self-renew but will lead to a 
production of a specific type of blood cell. 
The lineage commitment occurs through 
changes in gene expression, which is driven 
by growth factors activating signal 
transduction pathways that alter transcription 
factors. Epigenetic changes, which mark 
gene regulatory regions active, silenced, or 
poised, often proceed and accompany the 
gene expression changes of stem cell 
differentiation (Bernstein BE, et al. 2006; 
Doulatov S, et al. 2012).  
 
Specific bone marrow microenvironment 
often referred to as a “stem-cell niche” plays 
a key role in maintaining and regulating the 
 6 
self-renewal and differentiation of HSCs. 
Distinct local microenvironment can create 
asymmetry between HSCs by exposing two 
daughter stem cell to different extrinsic 
signals. Alternatively, asymmetric cell division, 
which results into differential distribution of 
the cell fate determinates, may initially 
coordinate the generation of both self-
renewing and differentiating daughter cells. It 
is plausible, however, that both 
environmental and divisional mechanisms for 
achieving asymmetry may be used in parallel 
by independent HSCs to guide daughter cells 
to distinct cell fates (Neumüller RA and 
Knoblich JA. 2009; Wilson A and Trumpp A. 
2006). 
In steady-state conditions, the bulk of the 
HSCs exist in the bone marrow while only a 
limited number of HSCs is circulating in the 
peripheral blood (Abkowitz JL, et al. 2003; 
Wright DE, et al. 2001). In these conditions, 
the majority of HSCs are slowly cycling 
(quiescent) cell populations, but can be 
induced to cycle actively in response to 
environmental cues. This ensures the proper 
homeostatic reconstitution of blood cells 
when needed. In addition, the quiescent state 
of HSCs protects cells from the damage 
related to deoxyribonucleic acid (DNA) 
replication and cellular oxidative metabolism 
(Orford KW and Scadden DT. 2008).  
 
 
 
Figure 1. The lineage differentiation of hematopoietic cells in human. Hematopoietic stem cells (HSC) express 
CD34 and CD49f among other markers. HSC give rise to multipotent progenitor cells (MPP), which are 
identified by the loss of CD49f marker. Only one population of immature multilymphoid progenitors (MLP) has 
been described, from which early T-cell precursors (ETP), progenitor B-cells (proB), natural killer cells (NK), as 
well as dendritic cells and monocytes derive. Several myelo-erythroid progenitors exist, namely: common 
myeloid progenitors (CMP), granulocyte-macrophage progenitors (GMP), and megakaryocyte-erythroid 
progenitors (MEP). Lineage marker (Lin) specifies the terminally differentiated populations. This illustration is 
based on the figure from Doulatov S et al. 2012. 
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1.1.2. Bone marrow stroma 
 
The bone marrow stromal cells are a 
heterogeneous population of cells, which 
include mesenchymal stem cells (MSCs), 
osteoblasts, osteoclasts, adipocytes, vascular 
endothelial cells, perivascular reticular cells, 
and smooth muscle cells. They play an 
essential role in regulating hematopoietic cell 
development as well as HSC maintenance 
and localization via the production of 
cytokines, chemokines, growth factors, and 
intracellular signals initiated by cellular 
adhesion (Morrison SJ and Spradling AC. 
2008; Konopleva MY and Jordan CT. 2011). 
For example, MSCs are multipotent stromal 
cells that provide a microenvironment that is 
favorable for hematopoiesis. They 
accomplish this by differentiating into the 
various cell lineages of the bone marrow 
stroma including, adipocytes, osteoblasts, 
osteocytes, fibroblasts, chondrocytes, and 
myoblasts. MSCs also form a scaffold for 
cell-cell interactions, and they secrete 
cytokines and growth factors such as C-X-C 
motif chemokine 12 (CXCL12) also known as 
stromal cell-derived factor 1 (SDF-1), 
macrophage colony-stimulating factor (M-
CSF), granulocyte colony-stimulating factor 
(G-CSF), granulocyte macrophage colony 
stimulating factor (GM-CSF), FMS-like 
tyrosine kinase 3 ligand (FLT3L), leukemia 
inhibitory factor (LIF), as well as many 
interleukins (Majumdar MK, et al. 2000 & 
1998; Baggiolini M. 1998; Deans RJ and 
Moseley AB. 2000; Konopleva M and Andreef 
M. 2007).  
 
Bone marrow stromal cells are also 
responsible for the production and deposition 
of a complex extracellular matrix (ECM), 
which mainly consist of fibronectin, hyaluronic 
acid (hyaluronan), collagen types I and IV, 
laminin, proteoglycans, hemonectin, 
thrombospondin, heparin sulfate, and 
chondroitin sulfate. In addition to the stromal 
cell derived growth factors and interactions 
between hematopoietic cells and stromal 
cells, hematopoietic cell interactions with 
ECM are required for the normal 
hematopoietic development. The ECM 
provides structural support as well as 
participates in controlling cell growth, survival, 
differentiation, motility, and viability through 
cell-ECM interactions. Importantly, growth 
factors, cytokines, and chemokines secreted 
by stromal cells can be concentrated in 
specific compartments within the bone 
marrow due to the differences in local 
production and through cytokine-binding 
glycosaminoglycans in the ECM. As such, the 
ECM serves as a reservoir of many secreted 
soluble proteins. The availability of these 
ECM tethered molecules can be regulated via 
re-arrangements of the matrix usually via 
degradation by proteases (Bonnans C, et al. 
2014; Marastoni S, et al. 2008). 
 
1.2. Bone marrow niches 
 
Bone marrow is divided into two distinct 
subcompartments termed “niches”, which are 
osteoblastic (endosteal) and vascular niches 
(Figure 2). According to their differentiation 
stage, HSCs and progenitor cells localize into 
these specific bone marrow 
microenvironments. These two different 
niches play an important role in controlling 
HSC fate by regulating quiescence, survival, 
self-renewal, and/or differentiation of these 
cells through interactions between 
hematopoietic cells and bone marrow stroma. 
The microenvironment of the niches is 
interconnected and forms a complex network, 
however, each niche influences HSCs 
differently (Tripodo C, et al. 2011; Perry JM 
and Li L. 2007; Konopleva MY and Jordan 
CT. 2011). 
 
1.2.1. Osteoblastic niche 
 
The osteoblastic niche, also called the 
endosteal niche or endosteum, is localized at 
the inner surface of the bone cavity, and is 
mainly composed of endosteal fibrocytes and 
osteoblasts. Osteoblasts are bone-forming 
cells derived from MSCs, and they play a 
critical role in regulating HSCs. The majority 
of HSCs in the endosteum are directly in 
contact with the osteoblasts, and in vivo 
studies in mice have demonstrated a 
simultaneous increase in bone formation and 
HSC numbers in bone marrow (Perry JM and 
Li L. 2007; Arai F and Suda T, et al. 2007; 
Calvi LM, et al. 2003; Zhang J, et al. 2003; 
Wilson A and Trumpp A. 2006; Tripodo C, et 
al. 2011). 
 
Specifically, osteoblastic content was 
increased via activation of parathyroid 
hormone receptor (PTH1R) (Calvi LM, et al. 
2003) or bone morphogenetic protein 
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receptor 1A (BMPR 1A) (Zhang J, et al. 
2003), which resulted in a simultaneous 
increase in bone marrow HSC content. As 
neither PTH1R nor BMPR 1A are expressed 
on HSC, this indicated that the effect was 
mediated by osteoblasts. In these studies, 
the regulation of HSCs by osteoblasts was 
suggested to occur via Notch ligand and N-
cadherin interactions (Calvi LM, et al. 2003; 
Zhang J, et al. 2003). However, more 
recently, it was reported that N-cadherin 
expression was not necessary for bone 
marrow HSC maintenance by osteoblasts 
(Kiel MJ, et al. 2009).  
 
The intimate physical associations between 
HSCs and osteoblasts provide regulatory 
support to hematopoietic cells. For instance, 
osteoblasts produce several hematopoietic 
cytokines such as G-CSF, GM-CSF, and LIF. 
It has also been demonstrated that 
osteoblasts are able to support hematopoietic 
cells in vitro and maintain long-term cultures 
(Porter RL and Calvi LM. 2008), as well as 
regulate HSC quiescence via 
Tie2/angiopoietin-1 signaling in the bone 
marrow (Arai F, et al. 2004). Furthermore, 
osteoblasts can produce osteopontin, an 
extracellular matrix glycoprotein, during 
active bone remodeling and the amounts can 
vary with the activation state of the cell 
(Porter RL and Calvi LM. 2008). This 
inducible production of osteopontin has been 
shown to negatively regulate the HSC pool 
size in vivo (Stier S, et al. 2005; Nilsson SK, 
et al. 2005).  
It is plausible that osteoblastic precursor cells 
may also contribute to HSC regulation. In fact, 
it has been reported that Nestin+ MSCs give 
rise to osteoblasts, and that depletion of 
Nestin+ MSCs inhibited HSC homing to the 
bone marrow as well as attributed to a 
significant reduction in HSC numbers in bone 
marrow in vivo (Mendez-Ferrer S, et al. 2010). 
 
1.2.2. Vascular niche  
 
The vascular niche comprises sinusoidal 
endothelial cells lining blood vessels as well 
as other vascular components such as 
smooth muscle cells and CXCL12-abundant 
reticular (CAR) cells. Vascular niche 
stimulates proliferation and differentiation of 
HSCs by supplying maturation and activation 
signals to differentiating cells and regulating 
the intravasation and extravasation of the 
foreign elements. For example, the vascular 
niche is responsible for regulating the release 
of mature hematopoietic cells, such as 
mature non-nucleated red blood cells (RBCs), 
platelets, and mature granulocytes, into the 
circulation (Kopp HG et al. 2005; Konopleva 
M, et al. 2009; Wilson A and Trumpp A. 2006; 
Tripodo C, et al. 2011). 
 
Several studies have suggested that bone 
marrow endothelial cell mediated signaling is 
required for HSC self-renewal and 
regeneration after myelosuppression (Butler 
JM, et al. 2010; Salter AB, et al. 2009; 
Hooper AT, et al. 2009; Kopp HG, et al. 
2005). For instance, delayed vascular 
regeneration and hematopoietic recovery in 
mice following total body irradiation was 
observed in vascular endothelial growth 
factor receptor 2 (VEGFR2)—/— mice (Hooper 
AT, et al. 2009). Similarly, systematic 
administration of anti-VEGFR2 antibody 
inhibited the engraftment of HSCs and 
prevented the hematopoietic reconstitution in 
irradiated mice (Hooper AT, et al. 2009). 
Significant delay in hematologic recovery was 
also observed in the studies where 
vasculogenesis was inhibited via blocking 
VE-cadherin or Tie2/angiopoietin signaling 
(Salter AB, et al. 2009; Kopp HG, et al. 2005). 
In effect, soluble factors produced by 
endothelial cells have been suggested to be 
responsible for HSC self-renewal and 
regeneration, including angiopoietin-like 5 
and insulin-like growth factor binding protein 
2 (IGFBP2), cytokines such as stem cell 
factor (SCF) and FLT3L, as well as a 
heparin-binding growth factor pleiotrophin 
(Himburg HA, et al. 2010; Kobayashi H, et al. 
2010; Zhang CC, et al. 2008; Chute JP, et al. 
2006). 
 
1.3. Oxygen levels 
 
Adenosine triphosphate (ATP) synthesis via 
oxidative phosphorylation is dependent on 
molecular oxygen (O2). In the peripheral sites, 
the partial pressure of O2 (PO2) is 
significantly lower than the atmospheric PO2, 
and depending on the cell type can also vary 
dramatically. HSCs, in particular, are often 
localized in hypoxic endosteal niches of the 
bone marrow (Chow DC, et al. 2001; 
Harrison JS, et al. 2002). In effect, 
localization of the HSCs to the compartments 
with limited O2 is advantageous to the cells 
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as O2 metabolism generates reactive oxygen 
species (ROS), which can in high levels 
induce senescence in stem cells. (Jang YY 
and Sharkis SJ. 2007). 
  
The balance of complex signals in the bone 
marrow microenvironment control the 
capacity of HSCs to retain cell cycle 
quiescence or self-renew and generate 
different lineages of hematopoietic cells. 
Undifferentiated states of HSCs are 
maintained by various factors, among which 
low PO2 (hypoxia) is a major player 
(Mohyeldin A, et al. 2010). Gradients of 
oxygen between 1% in the endosteal niche 
and 6% in the vascular niche exist in the 
human bone marrow (Mohyeldin A, et al. 
2010), and the most primitive HSCs with 
quiescent state reside in the hypoxic 
microenvironment (Grassinger J, et al. 2010; 
Winkler IG, et al. 2010; Parmar K, et al. 2007).  
 
 
 
 
 
Figure 2. Bone marrow microenvironment. Components of the bone marrow microenvironment include 
hematopoietic cells such as hematopoietic stem cells (HSC) and multipotent progenitor cells (MPP), 
osteoblasts, osteoclasts, mesenchymal stem cells (MSC), CXCL12-abundant reticular (CAR) cells, adipocytes, 
immune cells such as macrophages and regulatory T cells (Treg), neurons, endothelial cells, and extracellular 
matrix (ECM). 
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2. Pathogenesis of acute myeloid 
leukemia 
 
Leukemia is a hematologic malignancy that 
originates in the bone marrow. It is broadly 
divided into acute leukemia, which includes 
acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL), and chronic 
leukemia, which includes chronic myeloid 
leukemia (CML) and chronic lymphocytic 
leukemia (CLL). However other subtypes of 
leukemia also exist. The different types of 
leukemia may derive from a different cell-of-
origin, have different characteristic molecular 
abnormalities, and have different responses 
to a therapy. The focus of this literature 
review is on the pathology of AML, the 
second most common type of leukemia in 
adults, and the most frequent cause for 
leukemia-related deaths. 
 
In AML, molecular abnormalities accumulate 
in normal hematopoietic stem or progenitor 
cells leading to neoplastic transformation 
(Chen J, et al. 2010).! The cells that have 
become leukemic appear immature and 
abnormal, and are commonly referred to as 
“blasts”. They do not function normally and 
their granulomonocytic differentiation 
program is impaired.  
 
AML progresses rapidly and the disease 
burdens the bone marrow and often also the 
peripheral blood. This interferes with the 
normal hematopoietic cell production leading 
to cytopenias. In effect, bone marrow failure 
and tissue infiltration by circulating leukemic 
cells account for the presenting clinical 
symptoms of AML. However, the diversity in 
clinical symptoms among different patients is 
mainly due to differences in age and 
molecular abnormalities (Ghanem H, et al. 
2012). 
 
2.1. Molecular abnormalities 
 
AML is a heterogeneous group of myeloid 
malignancies, and the nature and number of 
the molecular abnormalities can differ broadly 
between patients. The two most commonly 
used classification models for AML subtypes 
are, World Health Organization system 
(Vardiman JW, et al. 2002 & 2008) and 
French-American-British system (Bennett J, 
et al. 1976). 
In principle, leukemia is characterized by 
recurring gene mutations and chromosomal 
aberrations that play a key role in 
leukemogenesis. In addition, epigenetic 
modifications lead to activation or repression 
of gene expression and therefore also affect 
the phenotype of leukemia cells (Chen J, et al. 
2010).! Other mechanisms, such as 
microRNA (miRNA) deregulation and copy 
number alterations likewise contribute to this 
disease (Chen J, et al. 2010; Eklund EA. 
2010).  
 
Chromosomal translocations that result in the 
generation of chimeric fusion proteins are 
frequent in leukemia. They cause 
transcriptional deregulation thereby directly 
contributing to leukemogenesis (Testa U. 
2011). Common chromosomal translocations 
in AML include the t(15;17) translocation, 
which generates the fusion gene with 
promyelocytic leukemia gene (PML) and 
retinoic acid receptor alpha (RARα or RARA) 
in acute promyelocytic leukemia (APL), and 
the t(8;21) translocation, which generates the 
fusion gene with runt-related transcription 
factor 1 (RUNX1) and RUNX1 translocated to 
1 (RUNX1T1) (also known as AML1-ETO 
fusion gene). These fusion genes impair 
proper differentiation of HSCs thus leading to 
uncontrolled growth (Watt CD and Bagg A. 
2010; Takahaski S. 2011). About 50-60% of 
newly diagnosed patients with AML have 
cytogenetic abnormalities (i.e., abnormal 
karyotype), and cytogenetic analysis at 
diagnosis is an important prognostic indicator. 
In general, the cytogenetic abnormalities in 
AML are classified into three groups: high, 
intermediate and low risk (Marchesi F, et al. 
2011; Hong WJ and Medeiros BC. 2011). 
Patients within the high-risk cytogenetic 
group are potential candidates for allogeneic 
HSC transplantation, while patients within the 
low-risk cytogenetic group will receive only 
standard chemotherapy (Blum W. 2008). The 
best treatment strategy for intermediate risk 
AML patients remains to be defined.  
In addition, subkaryotypic alterations, such as 
gene mutations, are an important factor in 
risk-group predictions and are now being 
incorporated into risk assessment categories 
(Watt CD, Bagg A. 2010). In effect, in a large 
subset (40-50%) of AML patients it is 
impossible to identify cytogenetic aberrations 
via conventional cytogenetics. Patients with 
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normal karyotype at diagnosis are usually 
categorized into the intermediate risk group 
(Ghanem H, et al. 2012; Marchesi F, et al. 
2011). Characteristically, these patients have 
a notable heterogeneity in clinical outcome, 
and can have very different responses to 
treatments. Molecular characterization is 
particularly important in this subset of AML 
patients (Marchesi F, et al. 2011).  
There are many acquired single gene 
mutations that are crucial to the development 
of AML (Gaidzik V and Döhner K. 2008). The 
whole-genome sequencing studies have 
shown that cytogenetically normal AMLs 
harbor approximately 750 somatic point 
mutations (Mardis ER, et al. 2009; Ley TJ, et 
al. 2008), however, a large portion of these 
mutations are predicted to be irrelevant to the 
pathogenesis of AML. Regardless, the 
number of genetic aberrations implies that 
the pathogenesis of AML is a complex 
multistep process, similarly to other cancers 
(Hanahan D and Weinberg RA. 2000 & 2011). 
According to the current model, AML is 
thought to arise from a series of genetic 
alterations that confer various types of 
proliferative and survival advantages 
(Ghanem H, et al. 2012). The absolute 
number of mutations required to cause AML 
is unclear, and it remains to be determined 
which of the mutations are “driver” mutations 
and which are “passenger” mutations. 
Several mutations that significantly contribute 
to leukemogenesis have been identified 
including the mutations in FMS-related 
tyrosine kinase 3 (FLT3), CCAAT/enhancer 
binding protein alfa (C/EBPA), RUNX1, 
additional sex combs like transcriptional 
regulator 1 (ASXL1), myeloid-lymphoid or 
mixed lineage leukemia (MLL), Wilms tumor 
(WT1) and nucleophosmin 1 (NPM1) genes 
(Takahaski S. 2011; Döhner K and Döhner H. 
2008; Mardis ER, et al. 2009; Falini B, et al. 
2005). The different types of molecular 
abnormalities have been extensively 
reviewed (e.g. Marchesi F, et al. 2011; Watt 
CD and Bagg A. 2010; Odenike O, et al. 
2011; de Thé H and Chen Z. 2010). 
Furthermore, gene expression can also be 
deregulated via other types of molecular 
abnormalities, such as epigenetic chromatin 
modifications and miRNA regulation (Conway 
O’Brien E, et al. 2014; Agirre X, et al. 2012; 
Plass C, et al. 2008). For example, mutations 
in genes, such as isocitrate dehydrogenase 1 
and 2 (IDH1/2), ten-eleven-translocation 
oncogene family member 2 (TET2), and DNA 
methyltransferase 3 alpha (DNMT3A) lead to 
aberrant methylation in AML cells (Figueroa 
ME, et al. 2010; Yan XJ, et al. 2011). 
Moreover, alterations in copy numbers, 
achieved by insertions, deletions, inversions 
and translocations, can all contribute to 
subkaryotypic modifications in genomic 
content, and subsequently alter gene 
expression. Several acquired copy number 
variations (CNV) have been identified in AML 
(Eklund EA. 2010). According to one report, 
24% of patients with cytogenetically normal 
AML and 40% of those with an abnormal 
karyotype had CNVs (Walter MJ, et al. 2009). 
Finally, acquired uniparental disomy (aUPD) 
– a phenomenon caused either by 
chromosomal non-disjunction or homologous 
recombination during cell division – 
contributes to malignant transformation by 
leading to loss of heterozygosity of mutated 
genes. It is associated with both loss-of-
function mutations of tumor suppressor 
genes and gain-of-function mutations of 
proto-oncogenes (Raghavan M, et al. 2008; 
Fitzgibbon J, et al. 2005; Sanada M, et al. 
2009) Notably, aUPD occurs in approximately 
15-32% of AML patients (Walter MJ, et al. 
2009; Akagi T, et al. 2009).  
 
The age and presenting white blood cell 
counts are also important prognostic factors 
that can be used to predict the clinical 
outcome in patients (Marchesi F, et al. 2011; 
Ghanem H et al. 2012). Temporal differences 
in leukemia-initiating cells affect the 
properties of leukemogenic cells as stem cell 
properties and self-renewal mechanisms alter 
with age (Levi BP and Morrison SJ, 2008), 
likely affecting the type of mutations that are 
capable of initiating cancer. Consistently, the 
mutation signature of leukemia varies with 
age, and many driver mutations are only 
found in elder patients (e.g., in FLT3, NPM1, 
and DNMT3A), while some are more 
commonly observed in young patients (e.g., 
translocations involving RUNX1, MLL, and 
nuclear pore complex protein Nup98-Nup96 
encoded by the gene NUP98. In contrast, 
mutations that do not have a temporal 
preference occur throughout all the ages (e.g., 
in RAS genes) (Magee JE, at al. 2012).  
Notably, somatic mutations in hematopoietic 
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cells accumulate over time, and clonal 
hematopoiesis strongly correlates with age, 
which is associated with increased risk of 
hematologic cancer and mortality (Jaiswal S, 
et al. 2014; Genovese G, et al. 2014). In 
effect, pre-leukemic clones might be present 
for years with no indication of a malignancy 
(Jaiswal S, et al. 2014; Genovese G, et al. 
2014; Welch JS, et al. 2012). It has been 
demonstrated that detectable clonal 
expansion is most frequently driven by 
mutations affecting DNMT3A, TET2, and 
ASXL1 genes (Jaiswal S, et al. 2014; 
Genovese G, et al. 2014). The bulk of the 
somatic mutations, however, are random 
events, and it has been shown that only one 
or two cooperating mutations are often 
sufficient to generate the leukemic clone 
(Welch JS, et al. 2012). In addition, these 
initial leukemic clones can subsequently 
acquire more cooperating mutations, which 
might yield a subclone with a more 
aggressive phenotype, therefore leading to 
disease progression and/or relapse (Welch 
JS, et al. 2012). Notably, the pre-leukemic 
clones have been shown to survive 
chemotherapy and persist in remission 
(Shlush LI, et al. 2014; Corces-Zimmerman 
MR, et al. 2014), thus providing a potential 
source for leukemia progression and disease 
relapse.  
Taken together, AML is a highly 
heterogeneous group of diseases that carry a 
vast amount of different cytogenetic and 
molecular abnormalities. 
 
2.2. Intrinsic heterogeneity in leukemia 
 
Beyond the heterogeneity observed among 
different patients, cancer cells within the 
same tumor can be highly heterogeneous 
and differ in morphology, marker expression, 
proliferation potential, and therapy resistance. 
These intrinsic differences are caused by 
genetic and epigenetic changes and they 
confer heritable phenotypic and functional 
differences upon cancer cells (Vermeulen L, 
et al. 2012). These changes are subject to 
selection within tumors – a process referred 
to as clonal evolution – and it often leads to 
more aggressive cancers over time (Magee 
JE, at al. 2012; Polyak K, et al., 2009; Bissell 
MJ and Hines WC, 2011). Whole-genome 
sequencing of samples from patients with 
secondary-AML and myelodysplastic 
syndrome (MDS) revealed that nearly all the 
bone marrow cells in these patients were 
clonally derived, and the genetic evolution 
occurs via multiple rounds of acquisition and 
clonal selection (Walter MJ, et al. 2012). 
Interestingly, recurrent genetic mutations 
were found in both the original leukemia-
initiating cells as well as in a subsequently 
evolved subclone selection (Walter MJ, et al. 
2012). Concomitantly, another study done via 
whole-genome sequencing demonstrated 
that accumulation of new mutations and 
clonal evolution occur in relapsed AML, and 
that these events are partially induced by the 
chemotherapy received for the primary AML 
(Ding L, et al. 2012). 
 
The heterogeneity among cancer cells within 
the same tumor can also arise in response to 
extrinsic influences, and cancer cells may be 
phenotypically and functionally different due 
to dissimilarities in the microenvironment 
surrounding them. These differences are 
often reversible, however, environmental 
changes could also cause irreversible 
alterations in cancer cell properties (Magee 
JE, at al. 2012; Polyak K, et al., 2009; Bissell 
MJ and Hines WC, 2011). 
 
The capacity for long-term replication and 
tumorigenicity also varies among cancer cells. 
Several studies have shown that, in the 
majority of cases, only a rare population of 
cells with immature phenotype has the 
capacity to replicate long-term, and they can 
be serially transplanted in mice (Magee JE, et 
al. 2012; Vermeulen L, et al. 2012). On the 
contrary, nontumorigenic cancer cells – 
although composing the bulk of tumors – are 
thought to have a limited self-replication 
potential and therefore have little contribution 
to cancer progression (Shackleton M, et al., 
2009; Dick JE. 2008; Reya T, et al., 2001). 
As such, the rare tumorigenic cancer cells 
are commonly referred to as cancer stem 
cells (CSCs), or cancer initiating cells. 
Importantly, the CSCs can originate via 
mutations that de-regulate self-renewal 
mechanisms in normal stem cells or in 
progenitor cells and more differentiated cells, 
and thus the term CSC does not imply the 
cell-of-origin (Magee JE, at al. 2012). Notably, 
CSCs resemble normal stem cells in that they 
can self-renew, have the capacity to 
proliferate long-term as well as have a 
potential to differentiate to multiple lineages. 
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This suggests that in cancers that follow the 
stem cell model, only a small subpopulation 
of cells can proliferate extensively and are 
therefore responsible for maintaining the 
neoplastic process. As such, therapies that 
only target the bulk of tumors may not be 
sufficient to cure the patient because they fail 
to eliminate cancer stem cells (Magee JE, at 
al. 2012). 
 
AML is one such cancer that is thought to 
follow a stem cell model in which intrinsically 
different subpopulations of tumorigenic and 
nontumorigenic cancer cells are hierarchically 
organized, and tumorigenic cancer cells 
differentiate into phenotypically diverse 
nontumorigenic cancer cells.  
 
The pioneering work in cancer stem cell 
research was carried out by John Dick’s 
laboratory, and was based on transplantation 
assays of AML cells into non-obese diabetic 
(NOD)/severe combined immunodeficiency 
(SCID) mice, which led to the idea that 
leukemia stem cells (LSCs) or leukemia 
initiating cells are rare and exclusively 
confined in the CD34+CD38- cell population 
(Lapidot T, et al. 1994). Since then, markers 
that would distinguish the LSCs from the 
remaining bulk of non-leukemogenic cells 
have been studied extensively. Moreover, the 
studies in new and improved 
xenotransplantation models have shown that 
cell populations acting as LSCs can have 
diverse membrane phenotypes in various 
types of AMLs, and thus LSCs are not only 
restricted to CD34+/CD38- populations 
(Testa U. 2011). In effect, several results 
imply that CSC-affiliated cell surface markers 
are more heterogeneous than initially 
comprehended (Testa U. 2011). However, 
recent results also propose that stem cell 
expression patterns may exists only in the 
blast cells at a population level, and that an 
individual blast cell would not have the 
complete repertoire or expression level of 
stem cell markers; therefore the blasts would 
be different from LSCs (Eppert K, et al. 2011).  
 
Nevertheless, xenotransplantation assays 
may considerably underrate the ratio of 
human cancer cells that have tumorigenic 
potential (Vermeulen L, et al. 2012; Eppert K, 
et al., 2011; Adams JM and Strasser A. 2008). 
In addition, the foreign microenvironment 
may only support the growth of certain 
subclones of the cancer. As such, syngeneic 
transfers of mouse leukemias or lymphomas 
have been used to shed light on the LSC 
model without the complexity of 
xenotransplantation. Interestingly, studies in 
AML murine models showed that leukemia 
initiating cells were numerous and rather than 
resembling a stem cell presented relatively 
mature phenotypes (Somervaille TC and 
Clearly ML. 2006; Krivtsov AV, et al. 2006). 
 
The leukemia-initiating cells can be very 
different from each other due to differences in 
oncogenic mutations that can have profound 
effects on the frequency and phenotype of 
these cells (Magee JE, at al. 2012). Moreover, 
recent studies have shown extensive 
plasticity and dedifferentiation in normal 
somatic tissue cells that obtain specific 
environmental inputs or, in an artificial setting, 
can be induced to become pluripotent stem 
cells when transduced with the right factors 
(Chaffer CL, et al. 2011; Gupta PB, et al. 
2011). These results suggest that 
differentiation of LSCs into non-leukemogenic 
cells may similarly be reversible, and this 
plasticity of LSCs may contribute to therapy 
resistance. However, the identification of 
markers that characterize the populations 
with leukemogenic capacity may still be 
possible if cells in the non-leukemogenic 
state only transform to the LSCs with low 
efficiency or under restricted circumstances 
(Magee JE, at al. 2012). 
 
Notably, cancers that develop according to 
the stem cell model are also subject to clonal 
evolution and environmental impact that can 
contribute to heterogeneity. Therefore all the 
sources of heterogeneity are cumulative 
rather than mutually exclusive, and different 
processes may be utilized at variable levels 
based on the type of cancer (Magee JE, at al. 
2012). 
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3. Emerging targeting approaches in 
acute myeloid leukemia 
 
High-dose chemotherapy has been the 
standard therapeutic approach for AML 
patients. This has consisted mainly of 
cytarabine combined with an anthracycline 
antibiotic, usually daunorubicin, idarubicin, or 
the anthracedione mitoxantrone (Burnett A, et 
al. 2011, Tallman MS, et al. 2005). In general, 
treatment of AML with chemotherapy is often 
initially successful and approximately 60% to 
70% of adult patients are expected to achieve 
complete remission (CR). However, disease 
relapse occurs in many patients, and duration 
of CR is shorter in patients older than 60 
years (Mayer RJ, et al. 1994). Therefore the 
overall prognosis is poor in AML and the 
overall 5-year survival rate is only around 
25% according to National Cancer Institute. 
In addition, depending on the AML subtype, 
survival rates can vary intensely. In particular, 
successful treatment outcomes have been 
obtained with APL, in which all-trans retinoic 
acid (ATRA) and arsenic trioxide are used 
alone or in combination with chemotherapy to 
target the PML/RARA fusion gene (de Thé H 
and Chen Z. 2010; Sanz MA, et al. 2009). 
However, although differentiation therapy 
induces remission it is rarely curative. In 
addition, some improvement in survival rates 
has been obtained over the past decades 
even with the conventional chemotherapy 
drugs; however, this is mostly attributable to 
advancements in supportive care needed 
against severe cytopenias caused by 
effective treatments (Burnett A, et al. 2011).  
 
The difficulty of targeting and fully eradicating 
leukemia cells is a major cause of relapse, 
and most patients with AML die from 
progressive disease after relapse (Ding L, et 
al. 2012). Chemotherapy although required to 
induce initial remission, contributes to new 
mutations and clonal evolution. In essence, 
treatment can change the dominance of a 
clone causing a selection of one or more rare 
clones that survive the therapy because of 
new or already existing genetic mutations 
(Ding L, et al. 2012). In addition to acquiring a 
new set of mutations, the secondary AMLs 
carry over all the pre-existing mutations from 
primary clones, thus resulting in subclones 
with increased numbers of mutations. 
Secondary AMLs are therefore mixtures of 
several genomes with unique sets of 
mutations (Walter MJ et al. 2012).  
 
Targeted therapies against different disease-
driving molecular aberrations, aberrantly 
activated signaling pathways as well as 
alternative compensatory molecular networks 
are desperately needed to fully eradicate 
AML (Hopkins AL. 2008).  
  
3.1. Abnormally activated signaling 
pathways 
 
Targeting of signaling pathways that are 
aberrantly activated in leukemia are likely to 
improve therapy outcomes. For instance, 
several signaling pathways are constitutively 
activated in leukemia, such as the Janus 
kinase (JAK)/signal transducers and 
activators of transcription (STAT) pathway as 
well as the nuclear factor kB (NF-kB) and the 
phosphatidylinositol-3-OH kinase (PI3K) – 
Akt/protein kinase B (PKB), pathways. The 
constitutive activation can be caused by 
abnormal autocrine and/or paracrine 
signaling from the tumor microenvironment, 
particular genetic aberrations or epigenetic 
deregulation (Chen E, et al. 2012).  
 
For example, a common feature in many 
hematopoietic malignancies as well as solid 
tumors is persistent STAT signaling, utilized 
by several cytokines, including interleukin-6 
(IL-6), IL-10, IL-11, IL-15, IL-23, GM-CSF, 
interferon alpha (IFN-  ), and interferon 
gamma (IFN-) (Bromberg J. 2002; Bowman 
T, et al. 2000). STAT3 signaling is 
constitutively activated in several leukemia 
cell lines as well as in primary leukemia cells, 
including AML (Chen E, et al. 2012; Redell 
MS, et al. 2011; Zhao J, et al. 2011; Ma LD, 
et al 2010; Ferrajoli A, et al. 2006). Persistent 
STAT3 activation has been reported to 
increase survival, proliferation, angiogenesis 
and metastasis, as well as decrease anti-
tumor immunity (Sansone P and Bromberg J. 
2012; Yu H, et al. 2009), and is associated 
with invasive phenotype (Ranger JJ, et al. 
2009; Suman P, et al. 2009) and poor patient 
prognosis (Chatterjee D, et al. 2008).  
 
The PI3K – Akt/PKB pathway – utilized by 
growth factors binding to receptor tyrosine 
kinases, such as insulin-like growth factor 
(IGF-1), vascular endothelial growth factor 
(VEGF), and some epidermal growth factor 
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(EGF) family members (Engelman JA. 2009) 
– has an essential role in proliferation, 
survival, metabolism, differentiation and 
migration of many different cell types, 
including hematopoietic cells (Polak R and 
Buitenhuis M. 2012; Cully M, et al. 2006; 
Stiles B, et al. 2004). In AML, several 
different abnormalities, including FLT3, RAS 
or c-KIT mutations, as well as 
autocrine/paracrine secretion of growth 
factors, such as IGF-1, VEGF, have been 
shown to upregulate the PI3K/Akt pathway 
(Martelli AM, et al. 2006 & 2009). 
 
NF-  B signaling is often constitutively 
activated in solid and hematological 
malignancies (Luo J-L, et al. 2005). NF-B is 
activated by many different stimuli, such as 
proinflammatory cytokines including IL-1 , 
tumor necrosis factor- (TNF-), and EGF, 
T- and B-cell mitogens, viruses and viral 
proteins, bacteria and lipopolysaccharides, 
double-stranded RNA, and chemical as well 
as physical stresses (Aggarwal BB and Sethi 
G and Aggarwal BB. 2006). In addition, 
cellular stresses such as ionizing radiation, 
hypoxia, and chemotherapeutic agents also 
activate NF-B (Sethi G and Aggarwal BB. 
2006; Sethi G, et al. 2008). The NF-B 
pathway regulates genes that promote 
inflammation, proliferation, survival, 
angiogenesis, invasion, and metastasis 
(Sethi G, et al. 2008). In addition, many 
cancer cells utilize NF-  B signaling to 
achieve resistance to anti-cancer drugs, 
radiation, and cell-death cytokines (Luo J-L, 
et al. 2005). Specific mutations in c-KIT, 
FLT3 and RAS, which lead to constitutive 
activation of the NF-B pathway, have been 
reported in AML. Increased IL-1 production 
has also been reported to activate NF-B 
signaling in AML (Estrov Z, et al. 2003 & 
1999). Atypical NF-B pathway also exists, 
which can be activated through IKK-
independent mechanism via stimuli, such as 
hypoxia, oxidizing radicals, or ultraviolet light 
radiation, leading to IB phosphorylation, 
ubiquitination, and degradation (Perkins ND. 
2007). 
 
In addition, several other signaling pathways 
contribute to leukemogenesis. For example, 
Notch, Wnt, Hedgehog, and transforming 
growth factor beta (TGF-)/Smad signaling 
play important roles in regulating fate of both 
normal and malignant HSCs (Pajcini KV, et al. 
2011; Irvine DA and Copland M. 2012; 
McCubrey JA, et al. 2014; Blank U and 
Karlsson S. 2011). 
 
3.2. Altered metabolism 
 
Since 1920, altered metabolism has been 
recognized as one of the major differences in 
cancer cells and normal cells when Otto 
Warburg established that the majority of 
cancer cells produce large amounts of lactate 
even in the presence of oxygen (Warburg O, 
et al. 1924; Warburg O. 1925). This 
phenomenon is often referred to as the 
“Warburg effect”. Several subsequent studies 
have shown the preference of cancer cells to 
metabolize glucose via aerobic glycolysis 
(Deberardinis RJ, et al. 2008; Hsu PP and 
Sabatini DM. 2008), which likely enables 
faster proliferative metabolism (Vander 
Heiden MG, et al. 2009). 
 
It is now known that genetic and epigenetic 
alterations in oncogenes and tumor 
suppressor genes trigger changes in several 
intracellular signaling pathways that take part 
in tumor cell metabolism, leading to 
modifications in the cell survival and growth 
(Cairns RA, et al. 2011). In addition, the 
malignant tumor microenvironment – which 
includes components such as hypoxia as well 
as low pH and glucose levels – plays a key 
role in controlling the metabolic phenotype of 
tumor cells, consequently driving the tumor 
cells to adapt their metabolism to these 
extreme conditions (Cairns RA, et al. 2011). 
Moreover, altering cellular metabolism toward 
macromolecular synthesis is important in 
providing sufficient amount of building blocks 
for a proliferating cell to increase their 
biomass prior to cell division (Ward PS and 
Thompson CB. 2012). However, most 
proliferating cancer cells still gain a 
substantial portion of their ATP through 
oxidative phosphorylation (Ward PS and 
Thompson CB. 2012). Proliferating cancer 
cells also use mitochondria as a functional 
biosynthetic organelle, and glutamine is a 
primary carbon source for this type of 
mitochondrial metabolism (Ward PS and 
Thompson CB. 2012). 
 
Many aberrations in metabolic pathways 
have been reported in AML. For example, the 
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metabolic enzymes IDH1 and IDH2 are 
frequently mutated in AML and associated 
with unfavorable prognosis (Mardis ER, et al. 
2009; Green A and Beer P. 2010; Thol F et al. 
2010 & 2010; Wagner K, et al. 2010). The 
mutations cause the normal enzymatic 
function – conversion of isocitrate to  -
ketoglutarate – to be impaired, while resulting 
into a gain of function – conversion of -
ketoglutarate to R-2-hydroxyglutarate (R-2HG 
or D-2HG) (Gross S, et al. 2010; Dang L, et 
al. 2009; Ward PS, et al. 2010). The 2HG 
metabolite can competitively inhibit  -
ketoglutarate dependent enzymes, such as 
ten-eleven-translocation oncogene family 
member 2 (TET2) and the Jumonji C (JmjC) 
histone demethylases, thus leading to 
impaired epigenetic regulation and 
contributing to progression of leukemia (Ward 
PS and Thompson CB. 2012; Ko M, et al. 
2010; Xu W, et al. 2011). It has recently been 
shown that pharmacological inhibition of 
mutant IDH1 efficiently blocked the colony 
formation of AML cells derived from patients 
carrying this mutation, while no effect was 
observed in normal hematopoietic cell 
progenitors (Chaturvedi A, et al. 2013). 
 
A study with hundreds of AML patient 
samples and healthy control samples 
revealed an altered glucose metabolism 
signature in AML, and enhanced glycolysis 
reduced sensitivity to anti-leukemic therapy in 
vitro (Chen W-L, et al. 2014). Importantly, 
several serum metabolites involved in 
glucose metabolism were identified to have 
prognostic value in cytogenetically normal 
AML (Chen W-L, et al. 2014). 
 
Furthermore, the deregulated metabolism of 
ROS may also have therapeutic value in AML. 
Excessive production of ROS has been 
reported in many cancers including leukemia, 
and shown to be important for the regulation 
of HSC population (Ito K, et al. 2006). It has 
been demonstrated that the Forkhead 
transcription factor (FOXO) family of genes 
plays a critical role in HSCs by mediating 
resistance to physiological oxidative stress 
(Tothova Z, et al. 2007). Inhibition of the 
FOXO activity and its downstream 
constituents was found to diminish 
leukemogenic potential in MLL-AF9 AML 
mouse models (Sykes SM, et al. 2011). 
 
Taken together, targeting of the altered 
metabolism is a promising endeavor in the 
development of new therapies.  
 
3.3. Leukemia stem cells 
 
LSCs contribute to treatment failure and 
disease relapse due to their reduced 
sensitivity to chemotherapeutic agents. The 
mechanisms involved in LSC maintenance 
and self-renewal are therefore being 
investigated as targets for therapy 
(Konopleva MY and Jordan CT. 2011). 
 
However, one of the main obstacles in 
targeting LSCs is that treatment strategies 
must take into consideration that the cell 
cycle status of LSCs is mostly quiescent. 
Therefore, therapies must be able to target 
cells independent of their cell cycle status or 
activate LSCs prior to therapy (Konopleva 
MY and Jordan CT. 2011). For instance, 
Tie2/angiopoietin-1 signaling has been 
shown to suppress cell cycle progression in 
AML (Ichihara E, et al. 2011), and could 
therefore be a target for quiescent cells.  
 
In addition, targeting should be directed 
against properties that are most consistently 
aberrant in LSCs. Notably, several cell 
intrinsic mechanisms contribute to the LSC 
maintenance and self-renewal capabilities, 
such as constitutive activation of the NF-kB 
and the PI3K – Akt/PKB pathways, which 
increase reliance on anti-apoptotic 
mitochondrial proteins via overexpression of 
several B-cell CLL/lymphoma 2 (BCL-2) 
family members, and chromatin modifications 
(Guzman ML and Allan JN. 2014; Konopleva 
MY and Jordan CT. 2011). For example, NF-
 B pathway is constitutively activated in 
primary human AML stem cells, indicating 
that this pathway is important for overall LSC 
survival as well as for AML cells in general 
(Guzman ML, et al. 2001; Guzman ML, et al. 
2002). Interestingly, most of the compounds 
that have shown success to eradicate LSCs 
function as NF-  B pathway inhibitors 
(Hassane DC, et al. 2008). Therefore, this 
pathway is a promising target for the 
development of LSC-specific therapies 
(Konopleva MY and Jordan CT. 2011). 
Alternatively, the leukemogenic 
translocations, such as RUNX1-RUNX1T1 
and monocytic leukemia zinc finger-
transcirptional mediators/intermediary factor 
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2 (MOZ-TIF2), can enhance or confer self-
renewal properties to progenitor cells, and 
may therefore, be utilized for targeting 
purposes (Steffen B, et al. 2011; Huntley BJP, 
et al. 2004). 
 
In addition, LSCs have a unique phenotype 
and many cell surface markers are selectively 
expressed on LSCs. For example, it has 
been demonstrated that CD32 and CD25 
markers, specifically expressed in LSC 
population of most AML patients (Saito Y, et 
al. 2010), have both therapeutic and 
prognostic value. Other phenotypic markers 
currently under evaluation include, CD123 
markers (Jordan CT, et al. 2000), C-type 
lectin-like molecule-1 (CLL-1) (van Rhenen A, 
et al. 2007; Zhao X, et al. 2010), CD96 
(Hosen N, et al. 2007), T-cell immunoglobulin 
and mucin domain 3 (TIM-3) (Jan M, et al. 
2011), CD47 (Majeti R, et al. 2009), CD44 
(Jin L, et al. 2006), interleukin-1 receptor 
accessory protein (IL1RAP) (Askmyr M, et al. 
2013), as well as Tie2 and N-cadherin (Qiu S, 
et al 2014). 
 
A variety of cell-extrinsic mechanisms are 
also involved in LSC maintenance and self-
renewal, such as microenvironmental 
signaling, cell-cell contact, and oxidative 
stress. Promising therapeutic strategies 
include targeting of the mechanisms that 
mediate LSC adhesion within bone marrow 
niches as well as the pathways responsible 
for niche-induced prosurvival and self-
renewal signaling in LSCs (Konopleva MY 
and Jordan CT. 2011).  
 
3.4. Leukemia microenvironment 
 
The normal HSC niche ensures HSC survival 
and self-renewal, thereby ensuring life-long 
hematopoiesis. In part, this is accomplished 
by forming privileged sites that maintain 
cellular quiescence. Similarly, LSCs can 
benefit from these sites in order to promote 
their survival by escaping immune system, 
evading apoptosis, and acquiring self-
renewal capacity (Raaijmakers MHGP. 2011). 
Leukemia cell growth creates a malignant 
microenvironment that has the capacity to 
suppress normal hematopoiesis by impairing 
normal HSCs and MPPs. For instance, 
leukemic cells can take over existing bone 
marrow niches and subsequently utilize the 
signaling mechanisms of these niches for 
their maintenance and survival. Leukemia 
cells were demonstrated to specifically 
disrupt the niches of normal HSCs in the 
experiments utilizing in vivo imaging 
(Colmone A, et al. 2008; Sipkins DA, et al. 
2005).  
 
Moreover, the disruption of heterotypic 
signaling between HSCs and their niche may 
promote the initiation of cancer, and it has 
been demonstrated that abnormal bone 
marrow stromal microenvironment on its own 
can lead to dysfunctional hematopoiesis and 
even induce secondary leukemia. These data 
indicate that primary changes in the bone 
marrow microenvironment can drive 
leukemogenesis (Raaijmakers MH, et al. 
2010). Lineage fate can be determined by 
stromal clues, and thus, the 
microenvironment may also affect the lineage 
commitment of acute leukemia (Wei J, et al. 
2008; Konopleva MY and Jordan CT. 2011). 
Similarly, stem cell niches have the capacity 
to provide stem cell characteristics on the 
cells that occupy them. In effect, increasing 
evidence from solid tumors suggests that 
stemness of a cell can be modulated by the 
microenvironment and therefore is not a rigid 
feature. It is conceivable that the linear 
hierarchy in leukemia also has much more 
plasticity than thus far recognized 
(Raaijmakers MHGP. 2011). In addition, 
several studies have shown that pure 
populations of MSCs isolated from the 
patients with hematopoietic malignancies 
frequently carry karyotypic abnormalities, 
which in some cases are completely different 
from those observed in leukemic cells 
(Flores-Figueroa E, et al. 2005; Zhang W, et 
al. 1999; Bhatia R, et al. 1995; Blau O, et al. 
2007). Therefore, molecular and genetic 
changes not only in leukemia cells, but also 
in stromal cells may contribute to 
leukemogenesis. 
 
Importantly, the bone marrow stromal cells 
can protect malignant cells from 
chemotherapy-induced death by providing 
resistance to cell-cycle-dependent cytotoxic 
therapies (Raaijmakers MHGP. 2011). The 
molecular mechanisms responsible for 
maintaining quiescence in normal stem cells 
may also facilitate LSC survival, and both the 
vascular and osteoblastic niche play a critical 
role for survival, proliferation, and 
differentiation of LSCs (Konopleva MY and 
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Jordan CT. 2011). For instance, after high-
dose chemotherapy, remaining leukemia 
cells that manage to escape the treatment 
cluster and adhere to the blood vessels as 
well as to the endosteum, suggesting that 
leukemia cells obtain anti-apoptotic signals 
both from osteoblasts as well as from 
vascular endothelium (Ninomiya M, et al. 
2007). 
 
Therefore, strategies that block homing and 
adhesion of LSCs to a bone marrow niche 
and/or sensitize leukemia cells to a therapy 
are of high interest. For instance, disruption 
of adhesion signals such as interaction 
between CXCL12 and C-X-C chemokine 
receptor 4 (CXCR4), by interference with 
CXCR4 molecules, has shown promise in 
preventing the homing of LSCs (Burger JA 
and Peled A. 2009). In addition, the survival 
and proliferation of leukemic blasts are 
dependent on several adhesive interactions 
with stromal ligands, such as vascular cell 
adhesion molecule 1 (VCAM-1) and 
fibronectin in the ECM. These interactions 
are mediated by integrins, such as 1 and 
2 integrins in AML cells (Bradstock KF and 
Gottlieb DJ. 1995; Bendall LJ, et al. 1994). It 
was also shown that when cell-cycle 
dependent chemotherapy was combined with 
colony-stimulating factor (G-CSF) treatment, 
apoptosis and elimination of human primary 
leukemia initiating cells was greatly enhanced 
in vivo compared with chemotherapy alone 
(Saito Y, et al. 2010). Moreover, drugs that 
target the abnormally activated pathways 
within the niche (resulting from paracrine 
loops) might be able to ”normalize” the 
cancer-promoting microenvironment, which in 
turn might render cancer cells susceptible to 
a therapy (Grivennikov SI, et al. 2010). 
 
Taken together, promising treatment options 
for AML include drugs targeting the stromal 
components and the interactions within bone 
marrow microenvironment.  
 
3.5. Angiogenesis 
 
Angiogenesis is known to be a major 
contributor to cancer progression in solid 
tumors; however, it is also an important 
requirement for the development and 
progression of hematologic malignancies 
such as leukemias and lymphomas (Ayala F, 
et al. 2009). In effect, increased 
vascularization is observed in leukemias, 
including AML and ALL, as well as in various 
pre-leukemic disorders, such as MDS and 
myeloproliferative neoplasms (Hussong JW, 
et al. 2005). Both leukemic blasts (Padró T, 
et al. 2002) as well as bone marrow stroma 
(Litwin C, et al. 2002) promote angiogenesis 
by secreting growth factors and 
proangiogenic mediators such as VEGF, 
basic fibroblast growth factor and 
angiopoietins. For example, VEGFR, one of 
the key players in angiogenesis, normally 
expressed by endothelial cells, is also 
expressed by leukemia cells to support their 
survival, growth and migration, and often 
responds to both autocrine as well as 
paracrine VEGFs (Li ZW and Dalton WS. 
2006; Ayala F, et al. 2009). Almost two 
decades ago, clinical studies already 
suggested that VEGF levels might have 
potential prognostic value for survival rates in 
some high-risk AML patients, independent of 
blast count (Aguayo A, et al. 1999). More 
recently, a meta-analysis confirmed the 
prognostic significance of VEGF expression 
in AML (Guo B, et al. 2013). Similarly, the 
expression of angiopoietins and their receptor 
Tie2 has been shown in leukemic blasts 
(Loges S, et al. 2005), and high anigopoietin-
2 levels have been associated with 
unfavorable prognosis in AML (Friedler W, et 
al. 2008; Hou HA, et al. 2008; Schliemann C, 
et al. 2007). 
 
A recent study demonstrated that AML cells 
are capable of either fusing with the already 
established endothelium, or differentiating 
into endothelial-like cells. The localization of 
AML cells to the vasculature was shown both 
in patients as well as in a xenograft model 
(Cogle CR, et al. 2014). These fates may 
increase the AML cell survival, as well as 
provide a reservoir for AML cells. 
Endothelium may therefore serve as a site of 
residual disease in AML (Cogle CR, et al. 
2014). The data strongly emphasize the 
importance of also targeting the malignant 
vasculature in AML bone marrow.  
 
3.6. Hypoxia 
 
The hypoxia response pathway is vital for the 
proliferation and survival of hematopoietic 
progenitors during embryonic hematopoiesis 
but it also plays an important role in both 
solid and hematological malignancies 
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(Takubo K and Suda T. 2012). The major 
regulators of this pathway are the members 
of  /  heterodimeric transcription factor 
hypoxia-inducible factors (HIFs) (Harris AL. 
2002; Semenza GL. 2003; Semenza GL. 
2012). For example, activation of the HIF-1 
signaling pathway up- or down regulates the 
expression of numerous gene products 
controlling energy metabolism, glycolysis, 
angiogenesis, survival/death, proliferation, pH 
regulation, adhesion, migration, invasion, and 
immune tolerance (Semenza GL. 2012; Lu X 
and Kang Y. 2010; Brahimi-Horn MC, et al. 
2007).  Specifically, HIF-1 regulates the 
expression of several genes encoding 
angiogenic growth factors, such as VEGF, 
platelet derived growth factor B (PDGF-B), 
stromal cell-derived factor 1 (SDF1), 
angiopoietin 1 and 2, and placental growth 
factor (PGF) (Semenza GL. 2012). It has 
been shown that the overexpression of HIF-1
  might have a profound impact on the 
prognosis of patients with leukemia, including 
AML (Fiegl M and Spiekermann K. 2011). 
 
Notably, decreased oxygen availability 
induces drug resistance and favors tumor 
progression. Hypoxic zones are considered 
to be less responsive to radiotherapy due to 
decreased levels of oxygen-free radicals that 
are required to produce a sufficient amount of 
DNA damage to induce cell death (Moeller BJ, 
et al. 2007). In addition, cells residing in 
hypoxic regions are more resistant to 
therapies due to their mainly quiescent cell 
cycle status as well as reduced delivery of 
drugs via the circulation (Brahimi-Horn M et 
al. 2007). Consequently, approaches to 
target hypoxic tumor microenvironment to 
prospectively sensitize tumor cells to 
chemotherapy have been studied extensively. 
Some approaches have pursued to directly 
block HIF-1  activity, while others take 
advantage of hypoxia-activated prodrugs that 
are functional only under hypoxic conditions 
(Benito J, et al. 2011). For instance, hypoxia 
activated nitrogen mustard prodrug was able 
to efficiently inhibit leukemia cell growth in 
preclinical mouse models of human AML 
(Portwood S, et al. 2013). 
 
3.7. Modifiers and regulators of chromatin, 
and non-coding RNAs 
 
Aberrant epigenetics is playing a crucial role 
in leukemogenesis, including AML (Plass C, 
et al. 2008).  An extensive analysis of DNA 
methylation changes in AML was performed 
on a large cohort of clinically annotated 
patient samples, which revealed specific 
methylation patterns between different AML 
subtypes and CD34+ CD38- cells from 
healthy donors (Ley TJ, et al. 2013). In 
addition, altered levels of histone acetylation 
have been reported in many malignancies, 
and mutations in genes encoding 
acetyltransferases, such as CREB binding 
protein (CREBBP) and EA1 binding protein 
p300 (EP300) have been found in leukemia 
and lymphoma (Mullighan CG, et al. 2011; 
Pasqualucci L, et al. 2011).  
 
Furthermore, non-coding RNAs, such as 
miRNAs and long-non coding RNAs, have 
been demonstrated to affect the phenotype of 
a cell by regulating the transcription, stability 
or translation of encoding genes and their 
role in cancer has clearly been established 
(Ling H, et al. 2013). For example, miR-155 is 
overexpressed in many solid tumors and 
hematological malignancies, including AML 
(Faraoni I et al. 2009; Kong et al. 2010). In 
patients with cytogenetically normal AML, 
high miR-155 expression was associated with 
shorter disease-free and overall survival as 
well as with low CR (Marcucci G, et al. 2013). 
In addition, it was demonstrated that locked 
nucleic acid-based and nanoparticle-based 
inhibition of miR-155 decreases tumor growth 
in mouse models of lymphoma (Babar IA, et 
al. 2012; Zhang Y, et al. 2012). These data 
suggest that therapeutic targeting of miR-155, 
or other aberrantly regulated miRNAs, may 
also be similarly achievable in AML. 
 
3.8. Mitochondrial proteins and 
biogenesis 
 
Many cancer cells rely on deregulated 
apoptotic signaling for their survival, and are 
often dependent on anti-apoptotic proteins, 
such as BCL-2 protein (Brunelle JK and Letai 
A. 2009). The overexpression of anti-
apoptotic proteins has been reported to 
confer drug resistance, and several strategies 
to inhibit the anti-apoptotic proteins have 
shown promise in sensitizing AML cells to 
therapy (e.g. Rahmani M, et al. 2012; 
Konopleva M et al. 2012; Vo TT, et al. 2012). 
For instance, mitochondrial “priming” – which 
referrers to relative mitochondrial readiness 
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for apoptosis – can be used to evaluate the 
sensitivity of AML cells to chemotherapy. 
BCL-2 homology 3 (BH3) domain profiling, 
which was used as a measure for differential 
priming between malignant myeloblasts and 
normal HSCs, identified BCL-2 inhibition as a 
promising therapeutic target (Vo TT, et al. 
2012).  
 
In addition, higher rates of mitochondrial 
biogenesis are observed in leukemic cells. 
Inhibition of the mitochondrial translation was 
shown to be a potential therapeutic strategy 
in mouse models of human AML (Skrtic M, et 
al. 2011). As such, dependence of AML cell 
survival on mitochondrial proteins or function 
may have significant clinical implications. 
 
3.9. Genetic vulnerabilities 
 
Driver mutations in cancer have received 
much attention as they contribute to the 
“oncogene addiction”, a phenomenon that 
explains how cancer cells, although 
containing multiple genetic and epigenetic 
changes, remain dependent only on a few 
abnormalities for their survival and growth 
(Weinstein IB and Joe A. 2008). However, 
recent research has shown that passenger 
mutations could also in some cases be 
exploited in therapeutic targeting. Specifically, 
when tumor-suppressor genes undergo 
inactivation via homozygous deletion many of 
the neighboring (i.e. passenger) genes are 
also often affected, and may as a result 
expose cancer-specific therapeutic 
vulnerabilities when the collaterally deleted 
gene belongs to a family of functionally 
redundant genes that carry out an essential 
function. For instance, deletion of the 
glycolytic gene enolase 1 in glioblastoma is 
tolerated because of the expression of 
enolase 2. However, it was demonstrated 
that a specific silencing of enolase 2 via RNA 
interference inhibited the survival and growth 
of cancer cells. Therefore, targeting of the 
passenger-deleted genes encoding 
functionally redundant essential activities 
provide an effective treatment strategy for 
cancer that contain such collateral 
vulnerabilities in their genomes (Muller FL, et 
al. 2012). It is likely that similar collateral 
vulnerabilities that could be exploited for 
therapies may also exist in AML. 
 
3.10. Immunotherapy 
 
Leukemia cells have the capacity to modulate 
immune cells in a manner that creates an 
immunosuppressive bone marrow 
microenvironment, where both innate and 
adaptive immune responses are repressed. 
The presence of several different 
immunosuppressive mechanisms facilitates 
leukemia cells to escape from normal 
immune control, and contributes to 
proliferation, survival, and drug resistance of 
AML (Arpinati M and Curti A. 2014; Isidori A, 
et al. 2014). For instance, several studies 
have confirmed the role of regulatory T cells 
(Tregs) in promoting cancer immunotolerance 
(Beyer M and Schultze JL. 2006; Ustun C, et 
al. 2011; Szczepanski MJ, et al. 2009; 
D’Arena G, et al. 2011). For example, AML 
blasts are known to be capable of increasing 
the number of Treg cells both via direct and 
indirect mechanisms (Ustun C, et al. 2011). 
In addition, tumor hypoxia has been shown to 
promote the recruitment of Tregs 
(Facciabene A, et al. 2011). 
 
Modulation of the immune system in a 
manner that facilitates the immune system to 
eliminate cancer cells is therefore actively 
being investigated, and many immunotherapy 
options have already been demonstrated to 
control the development of AML both in 
preclinical and clinical studies. The 
immunomodulatory receptors (also referred 
to as checkpoint molecules), such as 
cytotoxic T-lymphocyte associated antigen-4 
(CTLA-4) and programmed death-1 (PD-1) 
receptor that are expressed on T cells, 
participate in mediating the 
immunosuppression induced by cancer. 
Accordingly, inhibition of CTLA-4, PD-1, as 
well as PD-ligand 1 (PD-L1) receptors has 
been successfully shown to promote the 
immune attack against cancer (Martner A, et 
al. 2013). In addition, adoptive cellular 
therapies – which include isolation of 
autologous T-cells followed by ex vivo 
modification and/or expansion and ultimately 
by reinfusion – are emerging effective 
therapy options (Smith EL, et al. 2014; 
Rambaldi A, et al. 2015).  
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4. Discovery of novel targets and 
therapeutic agents 
 
4.1. Druggable targets 
 
The druggable genome is a concept that 
refers to human genome that is susceptible to 
pharmacological interactions and 
concurrently participates in disease driving 
pathological mechanisms (Hopkins AL and 
Groom CR. 2002). 
 
In general, in biological systems, therapeutic 
agents can be developed against four types 
of macromolecules, namely: proteins, 
polysaccharides, lipids, and nucleic acids. 
However, it is often difficult to obtain effective 
therapeutic agents against the latter three 
macromolecules, as toxicity and non-
specificity are major issues with these types. 
Therefore, compounds that interfere with the 
activity of proteins are of high interest 
(Hopkins AL and Groom CR. 2002). 
 
Based on these limitations, the molecular 
targets against which commercially feasible 
drugs can be developed has been restricted. 
This perspective has also lead to the term of 
“the druggable genome”, which accounts for 
the ~30,000 genes representing the 
informational content of the human genome 
that express proteins. However, only a 
fraction of these distinct targets have been 
exploited in the current drug therapies, as 
many of the proteins have no obvious binding 
or enzymatic activity, or known substrates, 
and only a limited number of “druggable 
proteins” are associated with biochemical 
mechanisms involved in disease (Hopkins AL 
and Groom CR. 2002). In effect, it has been 
estimated that only about 2-5% of the human 
protein-coding genome (approximately 600-
1,500 gene products) may serve as potential 
drug targets based on their relevance to the 
disease and targetability by drugs (Hopkins 
AL and Groom CR. 2002; Rask-Andersen M, 
et al. 2014). Current established 
pharmaceuticals exploit about 555 of these 
distinct target genes (Hopkins AL and Groom 
CR. 2002; Rask-Andersen M, et al. 2014). 
However, these estimates are based on 
studies with small molecules that are 
compliant with the “rule-of-five” guidelines 
(see below), thus including only drug targets 
that are able to bind compounds with 
appropriate properties (Hopkins AL and 
Groom CR. 2002). As the collection of 
pharmaceuticals is expanding to include new 
biotechnological products and techniques, 
such as antisense oligonucleotides and 
adenoviral gene delivery, the druggable 
genome is broadening tremendously. 
Nevertheless, the druggable genome is still a 
finite concept, which has its limits despite the 
advances (Rask-Andersen M, et al. 2014).  
 
Markedly, human cancers display numerous 
molecular abnormalities compared to normal 
tissue, and a widespread heterogeneity 
between different types and subtypes of 
cancers also exists (Weinstein IB and Joe AK. 
2006). These abnormalities are all potentially 
druggable targets, which may be exploited for 
therapies. In effect, the increased knowledge 
of the disease – based on the advances in 
technologies including next-generation 
sequencing and other genomic technologies, 
genome-wide association studies, proteomics 
analysis, RNA interference studies such as 
synthetic lethality screens, and chemical 
biology – has led to the discovery of many 
new drug targets and drugs (Patel MN, et al. 
2013).  
 
Nonetheless, development of molecular 
targeted therapies is challenging and slow 
due to struggles in discriminating the 
pathologically relevant targets as well as 
evaluating the prognostic value of a 
specific mutation in the midst of all the other 
coexisting mutations. As such, information 
obtained from the discoveries in molecular 
pathogenesis has been difficult to translate 
into novel therapeutics (Döhner H and 
Gaidzik VI. 2011). Functional screening 
approaches that can identify efficient targeted 
therapy options against clinically significant 
molecular abnormalities are thus also needed. 
 
4.2. High-throughput screening assays 
 
A high-throughput assay refers to a 
methodology that is capable of rapidly 
screening a large number of pharmaceutical 
agents or therapeutic targets, and relies on 
automated handling and detection devices.  
 
High-throughput screening assays can be 
broadly divided into biochemical target-based 
assays and cell-based assays (Table 1.).  
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High-
throughput 
Screening 
methods 
  
Advantages Disadvantages Example 
references 
Small 
molecule 
phenotypic 
screening 
 
Enables discovery of new therapeutic 
agents.  
 
No prior knowledge of a target is required. 
 
Allow exploration of new phenotypes and 
new areas of biology via discovery of first-
in-class drugs as well as provide tools to 
study complete signaling pathways and 
molecular networks. 
 
Allow oncogenic pathway prediction by 
identifying pathway dependences: 
facilitates the identification of functionally 
important targets. 
 
Identification of small molecules 
interacting with biological molecules that 
lack small molecule tools. 
 
Allow the identification of enzyme 
inhibitors, receptor agonists and 
antagonist, as well as, allosteric inhibitors 
and protein-protein interactions 
  
Diversity of a small molecule compound 
library is imitated by the “chemical 
space” of its compounds, 
 
Identification of the mechanism of 
action for a compound can be difficult: 
target identification is a major 
challenge. 
 
Optimization of molecular properties of 
a candidate drug can be challenging, 
 
Prioritizing with “hits” to follow-up can 
be challenging. 
 
A compound may give different 
phenotypes depending on the screening 
platform used. 
 
Pathway dependency prediction: The 
effective drug target assessment large-
scale may rely on an algorithm, which 
could exhibit both false-positive and 
false-negative targets 
Eggert US. 2013 
 
Swinney D and 
Anthony J. 2011 
 
Hatzis C, et al. 
2014 
 
Tyner JW, et al. 
2013 
 
Functional 
genomic 
screening 
via RNA 
interference 
(RNAi)  
Facilitate oncogenic target identification 
and validation of therapeutic targets. 
 
Identification of molecular vulnerabilities in 
malignant cells  
Reliability of RNAi-based screens can 
be limited by false-positive hits resulting 
from off-target effects and false-
negative hits resulting from ineffective 
RNAi agents 
 
Druggability of the target may be 
challenging 
Tyner JW, et al. 
2009 
 
Tyner JW, et al. 
2008 
 
 
Phage 
display 
random 
peptide 
library 
screening 
No prior knowledge of a target is required. 
 
Can identify novel ligand-receptor pairs 
 
Identifies physiologically relevant targets 
 
Enables identification of “druggable” 
disease markers 
 
Validated ligands can subsequently be 
used in targeted drug delivery 
 
Peptides have benefits over antibodies: 
relatively simple in vitro synthesis and 
quality control, increased tissue 
penetration and diffusion, and rapid blood 
clearance 
In theory, the amino acid sequence 
diversity of a phage display peptide 
library increases exponentially with the 
number of randomized residues, 
however the practical diversity of a 
phage display library is limited by 
bacterial transformation efficiencies.   
 
The higher selection of a certain peptide 
over the other via the phage displayed 
peptide library screening could be 
paradoxical due to preferential coding 
utilization in bacteria. 
 
Libraries may also contain many 
peptide sequences that have no 
compatibility in human, therefore, 
limiting the diversity of physiologically 
relevant sequences. 
 
Sergeeva A, et al. 
2006 
 
Pande J, et al. 
2010 
 
Hanzeh-
Mivehround M, et 
al. 2013 
 
 
Table.1. Examples of cell-based high-throughput screening methods for the discovery of novel targets and 
therapeutic agents.
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In general, biochemical assays are specific to 
the target of interest and the homogeneous 
reaction environment provides minimized 
experimental variability. These types of 
assays can be used, for instance, to measure 
enzymatic activity, ion channels, receptor-
ligand binding, nuclear receptor and protein-
protein interaction. On the contrary, cell-
based assays also enable the study of 
physiologically relevant mechanisms such as 
regulatory networks and feedback 
mechanisms. In addition, cell-based assays 
do not require any prior knowledge of a direct 
molecular target and they allow for selection 
of cell permeable agents. Cell-based assays 
can also provide clues of acute toxicity. 
Consequently, approximately half of all high-
throughput screens are currently performed 
in cell-based assays (An WF and Tolliday N. 
2010).  
 
Several approaches can be used to identify 
potential anti-cancer agents via cell-based 
high-throughput screening assays. One 
strategy is to screen large chemical libraries 
to identify biologically active compounds that 
preferentially inhibit in vitro cell growth or 
induce apoptosis in cancer cells. Alternatively, 
more focused chemical libraries against 
certain protein families, such as kinases, 
facilitate the discovery of best available 
treatment options for a certain pathway 
dependency in an individual (Tyner JW, et al. 
2013). Similarly, advances in personalized 
treatment tailoring with available drugs have 
been obtained by combining molecular 
profiling with ex vivo drug sensitivity and 
resistance screens (Pemovska T, et al. 2013). 
 
Genes responsible for maintaining the 
malignant phenotype of specific cancer cells 
can be identified through using RNA 
interference (RNAi) such as siRNA libraries. 
Subsequently, drugs can be designed to 
target the proteins expressed by these genes 
(Weinstein IB and Joe AK. 2006). For 
example, RNAi-assisted protein target 
identification (RAPID) technology has been 
developed for the assessment of each 
member of the tyrosine kinase gene family as 
a target in leukemia patients (Tyner JW, et al. 
2009). 
 
In addition, other types of high-throughput 
display technologies have also been 
developed, such as phage display technology, 
which can be used to map ligand-receptor 
pairs specific to cancer cells (Sergeeva A, et 
al. 2006). The identified ligands can then be 
potentially used in disease diagnostics, 
profiling, imaging and therapy. For instance, 
the ligands can be linked with cytotoxic 
agents or proapoptotic peptides to design 
targeted therapy options. The efficacy of the 
particular ligand as a drug delivery agent will 
also help to determine the impact of the 
cancer specific target under study.  
 
4.3. Small molecule compounds  
 
The advantages of using small molecule 
compounds in the large-scale screening 
include the cost-effectiveness and ease in 
production. In addition, they are frequently 
internalized into cells and can therefore also 
interact with intracellular targets.  
 
4.3.1 Drug-like properties 
 
Living systems contain several physiological 
barriers that drugs must encounter in order to 
reach the therapeutic target, including cell 
membranes, pH, metabolic enzymes, and 
transporters. These barriers usually decrease 
the efficacy of a drug.  
 
Desirable drug qualities include good 
absorption and distribution, low metabolism, 
reasonable elimination, and low toxicity, 
collectively referred to as ADME/Tox 
(absorption, distribution, metabolism, 
excretion, and toxicity) properties (Kerns EH 
and Di L. 2008). Therefore, in addition to the 
pharmacological (e.g., efficacy and 
selectivity) properties, it is essential to 
optimize the physicochemical (e.g., solubility, 
permeability, chemical stability, and 
metabolic stability) and toxicological 
properties of compounds to increase the 
success in drug discovery (Kerns EH and Di 
L. 2008). For instance, lipophilicity of a 
compound is a major factor of many 
ADME/Tox properties.  
 
Those compounds that have sufficiently 
acceptable ADME properties as well as 
toxicity profiles to survive through the Phase I 
clinical trials are defined to have “drug-like” 
properties (Lipinski CA, et al. 1997). Based 
on these data, Lipinski and Verber 
established a set of guidelines – namely the 
“rule-of-five” – for structural (physico-
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chemical) properties of drug-like compounds 
(Lipinski CA, et al. 2001). These guidelines 
state that good absorption and permeability, 
and thus oral bioavailability, are likely when 
the molecular weight of a compound is ≤500 
daltons, the number of hydrogen-bond 
acceptors (i.e., nitrogen and oxygen 
molecules) is ≤10, the number of hydrogen-
bond donors (i.e., OH and NH groups) is ≤5, 
and the partition coefficient (1-octanol:water), 
LogP, is ≤5. These guidelines, although not 
absolute, can be quite effective and efficient 
in assessing compounds with good 
absorption and permeability properties (Kerns 
EH and Di L. 2008).  
 
The rule-of-five has been the only 
computationally derived filter for drug-
likeness acknowledged by both academia 
and industry (Ursu O, et al. 2011), and the 
commercially available small molecule 
compound libraries are typically based on 
these criteria. Nevertheless, the use of the 
current commercially available small 
molecule compounds may limit the discovery 
of druggable targets, as the libraries are still 
relatively simple and often comprise of similar 
compounds (Galloway WRJD, et al. 2010). 
The biological activity of a molecule depends 
largely on its three-dimensional arrangement 
of chemical features (often referred to as the 
“chemical space”) that can interact with a 
specific target, and is essential to generate a 
biological response. Therefore, it is likely that 
as the chemical libraries become more 
diverse, for instance as the scaffold diversity 
increases and thus the chemical space, novel 
druggable targets will emerge rapidly 
(Galloway WRJD, et al. 2010).  
 
Furthermore, poor pharmacokinetics 
(clearance, half-life, bioavailability, drug-drug 
interactions) can cause low drug 
concentration in the plasma and target tissue, 
thus leading to poor in vivo efficacy. For 
instance, transporters (e.g., P-glycoprotein) 
can significantly affect the ADME/Tox 
characteristics of a compound. In addition, 
compounds may be instable in blood. For 
example, enzymatic hydrolysis, plasma 
protein binding, and red blood cell binding 
can hinder drug efficacy in the blood stream 
(Kerns EH and Di L. 2008). Other 
environmental factors, such as stromal cells 
and hypoxia, also affect drug stability and 
efficacy (Tabe Y and Konopleva M. 2014). 
Therefore, drug-like properties alone are not 
often sufficient to reflect whether a drug will 
be clinically efficacious.  
 
4.3.2 Target Identification 
 
Target identification of drug-like small 
molecules is crucial for understanding the 
biological phenomena at the molecular level 
as well as elucidating the mechanism of 
action of bioactive compounds (Takakusagi Y, 
et al. 2010). Nevertheless, targets for some 
drugs that are in clinical use or development 
still remain elusive. Comprehensive 
mechanistical analysis on these functional 
compounds and their target identification will 
likely provide new insight into druggable 
pathways and molecules (Rix U and Superti-
Furga G. 2009). 
 
Unfortunately, target discovery of small-
molecules remains a challenging and time-
consuming process. One factor that hinders 
target discovery is a lack of versatile methods 
to elucidate the mechanism of action of small 
molecules. In addition, bioactive small 
molecules often strongly or weakly interact 
with numerous targets, mainly proteins, in 
vivo. It is therefore technically challenging to 
thoroughly understand the molecular 
mechanisms of drug-like small-molecules 
(Takakusagi Y, et al. 2010). 
 
However, advancements in the development 
of experimental methods, as well as the 
arrangement of the genome database have 
facilitated the target identification. For 
instance, associating results from functional 
assays, such as cell viability and proliferation 
assays, with alterations in drug-induced 
transcriptomic profiles can identify cellular 
processes affected by a given treatment 
(Hatzis C, et al. 2014), therefore narrowing 
down the candidate targets. 
 
Furthermore, diverse technologies can be 
combined to act synergistically in order to 
increase throughput as well as to facilitate 
identification of targets for small molecules. 
Of the experimental technologies available, 
phage display technology enables rapid and 
extensive screening for peptides and proteins 
that interact with drugs. The homology 
studies of the discovered drug-binding 
peptides can, in turn, help to uncover the 
natural target for the small molecule under 
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study (Takakusagi Y, et al. 2010). In addition, 
the phage display technology can be utilized 
in identification of novel targets, for instance, 
via screening the phage-display peptide 
libraries against cancer cells, therefore 
making it as a valuable methodology in 
cancer target discovery. Several other display 
technologies also exist, such as cell-surface 
display, which may similarly be utilized in 
target identification for small molecule 
compounds (Sergeeva A, et al. 2006). 
 
4.4 Peptide based therapeutics 
 
Peptide-based therapeutics have many 
advantages compared to monoclonal 
antibodies including their smaller size, ease 
of derivatization, simplicity of in vitro 
synthesis as well as quality control, which 
reflect the lower cost of manufacturing. The 
peptides also have increased tissue 
penetration and diffusion, as well as faster 
blood clearance compared to antibodies 
(Sergeeva A, et al. 2006). Nevertheless, the 
therapeutic efficacy of peptides can be limited 
due to low affinity, potential immunogenicity, 
proteolytic degradation, and rapid renal 
filtration.  
 
The pharmacodynamic properties of peptide 
therapeutics may be improved by several 
approaches. For instance, enhanced stability 
of peptides has been obtained by use of 
scaffold proteins, blocking of N- and C termini, 
peptide cyclization, and substitution of L-
amino acids with D-amino acids, unnatural 
amino acids, and chemically modified amino 
acids. Polyethylene glycol and polysialic 
acids in conjugation with the peptide has led 
to longer peptide half-life, improved stability 
and decreased immunogenicity. In addition, 
secondary biased library screening and 
peptide multimerization have helped to 
improve the affinity of peptides (Krumpe LRH 
and Mori T. 2007). Therefore, development of 
peptides with enhanced therapeutic efficacy 
could include an initial screening of a 
combinatorial random peptide library to 
identify targeting prototype-moieties followed 
by subsequent screening of a secondary 
synthetic combinatorial peptide library that is 
based on the targeting moiety (Krumpe LRH 
and Mori T. 2007). 
 
Phage display technology is an excellent 
screening tool for the identification of lead 
targeting moieties. For example, the phage 
displayed random peptide libraries can be 
used to identify peptide sequences that bind 
to specific targets. Importantly, the ability of 
phage display technology to identify peptide 
leads that can be engineered into efficient 
therapeutics and targeting moieties has been 
well established by many research groups 
(e.g. Sergeeva A, et al. 2006; Krumpe LRH 
and Mori T. 2007). 
 
4.5. Phage display technology 
 
Phage display technology utilizes 
combinatorial libraries of exogenous peptides 
(or proteins) that are expressed on the 
surface of phage particles (Figure 3). These 
libraries can be screened against purified 
targets as well as live cells. The advantage of 
the phage display technology is that no prior 
knowledge about cell surface targets is 
required, and the target does not need to be 
immunogenic (Samoylova TI, et al. 2006; 
Sergeeva A, et al. 2006; Pande J, et al. 2010).  
 
In principle, a phage-display peptide library 
contains a wide diversity of peptide 
sequences and those with binding affinity 
against the desired target (i.e., a specific type 
of cell or molecule) can be selected via 
screening, yielding a set of peptide motifs 
that bind to the target under study. 
Importantly, the selected peptide motifs 
usually bind receptors by mimicking biological 
ligands of these receptors (Sergeeva A, et al. 
2006).  
 
One of the major challenges in clinical 
oncology today is that therapeutic agents 
cannot be selectively delivered to the tumor 
site without causing toxicity to the rest of the 
body. Importantly, phage display technology 
enables the identification of ligands that bind 
to targets selectively expressed in certain 
cancers. These tumor-specific receptors and 
corresponding ligands can subsequently be 
applied toward rational drug design for 
cytotoxic agents, gene therapy vectors, and 
for target-directed delivery of therapeutic 
agents and imaging agents (Ruoslahti E. 
2002; Kolonin MG, et al. 2001; Sergeeva A, 
et al. 2006). For instance, it has been 
demonstrated that phage particles displaying 
peptide and antibody ligands that bind to 
internalizing receptors, such as integrins, can 
undergo efficient uptake by target cells 
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(Zurita AJ, et al. 2004; Gao C, et al. 2003). 
Phage display technology has also been 
successfully utilized for targeted gene 
delivery into mammalian cells (Hajitou A, et al. 
2006; Poul MA and Marks JD. 1999; Larocca 
D, et al. 1999).  
 
Taken together, the phage display technology 
enables the identification of lead molecules 
for the development of novel agents that can 
potentially be utilized to specifically and 
effectively diagnose and treat cancer, and 
thus it has the potential needed for 
development of targeted anti-cancer 
therapeutics as well as diagnostic 
applications (Samoylova TI, et al. 2006). A 
number of comprehensive reviews list 
peptide motifs and their corresponding 
ligand/receptor systems discovered via 
phage display technology (e.g. Uchiyama F, 
et al. 2005; Landon LA and Deutscher SL. 
2003; Watt PM. 2006). 
 
4.5.1. Filamentous phage 
 
Filamentous bacteriophages (Inovirus) are a 
group of closely related viruses that 
selectively infect gram-negative bacteria. 
Contrary to other phages, such as the T4 
phage, filamentous bacteriophages are non-
lytic and they replicate and assemble without 
killing the host cells. The best-known 
filamentous phages are Ff phages, namely: 
fd, f1, and M13, which are virtually identical 
strains. Ff refers to those filamentous phages 
that require the interaction with F pili (surface 
protein normally used for interbacterial 
conjugation) to infect the host bacteria, such 
as Escherichia coli (Marvin DA. 1998; 
Rasched I and Oberer E. 1986).  
 
The structure of the filamentous phage M13 
has been investigated extensively. The 
filamentous phage particle is long and thin 
(930 nm in length and 6.5 nm in diameter) 
with a flexible rod shape structure. Their 
genetic material consists of a circular single-
stranded DNA (ssDNA) genome, which is 
about 6,000-8,000 bases and is enclosed in a 
coat comprised of five different proteins, 
specifically: pIII, pVI, pVII, pVIII, and pIX. 
Each phage contains about 2700 copies of 
the pVIII, the major coat protein that covers 
the length of the phage. Five copies of each 
of the two minor coat proteins, pIII and pVI 
cap one end of the phage, while 3 to 5 copies 
of pVII and pIX comprise the other end. In 
addition, the M13 phage encodes 6 other 
proteins, which participate to DNA replication 
and assembly (Kehoe JW and Kay BK. 2005; 
Pande J, et al. 2010).  
 
The infection is initiated when the phage’s 
coat protein pIII binds via its N2 domain to F 
pilus of the host cell. Phage binding causes 
the pilus to retract until the phage reaches 
the surface of the bacterium and binds, via 
the N1 domain of the pIII protein, to the 
membrane protein TolA of E.coli. The phage 
transfers its genome into the host cell once 
contact with the bacterial surface has been 
established. This leads to the disassembly of 
the infecting phage and insertion of the coat 
proteins into the bacterial membrane. The 
phage genome inside the bacterium is 
converted to double-stranded DNA by 
bacterial enzymes and the synthesis of 
phage proteins is initiated. Upon synthesis, 
the structural coat proteins spontaneously 
insert into the inner membrane of the 
bacterium. Following the replication of ssDNA 
genomes, the proteins assemble into a phage 
particle, and are extruded from the cells via 
the protein complex, consisting of the integral 
membrane proteins pIV, pXI, and pI, 
commonly referred to as a membrane pore. 
As the filamentous phage do not kill host cells, 
infected bacteria continue to grow and divide 
indefinitely, however, at half the rate of 
uninfected cells (Kehoe JW and Kay BK. 
2005; Pande J, et al. 2010). 
 
4.5.2. Phage display random peptide 
libraries 
 
The original phage display system was used 
for the affinity selection of protein fragments 
expressed from complementary DNA (cDNA) 
fragments (Smith GP. 1985; Parmley SF and 
Smith GP. 1988). Subsequently, other types 
of phage display libraries were developed for 
the affinity selection of peptides and 
antibodies (McCafferty J, et al. 1990; Devlin 
JJ, et al. 1990; Scott JK and Smith GP. 1990; 
Marks JD. et al. 1991; Barbas CF, et al. 
1991; Breitling F, et al. 1991; Hoogenboom 
HR, et al. 1991). Since then, a large number 
of phage displayed peptide and protein 
libraries have been constructed (reviewed in 
Hoogenboom HR. 2002, Szardenings M. 
2003, Kehoe JW and Kay BK. 2005; 
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Sergeeva A, et al. 2006; Paschke M. 2006; 
Pande J, et al. 2010).  
 
Combinatorial peptide libraries provide a 
useful tool to identify ligands with different 
binding potential (Sergeeva A et al. 2006). 
The most frequently utilized phage display 
libraries are the random peptide libraries 
(Pande J et al. 2010), which can contain 
about 1010 individual phage clones with a 
unique peptide sequence (Kehoe JW and 
Kay BK. 2005; Sergeeva A et al. 2006). 
Structurally more constrained phage display 
random peptide libraries have shown higher 
affinity to several targets to which more 
flexible linear random peptide libraries failed 
to bind (Pande J, et al. 2010). Accordingly, 
the most commonly used peptide libraries 
comprise of sequences with the general 
structure CXNC, which express peptides with 
random 5 to 9 amino acid residues that are 
flanked by cyclized cysteines (Sergeeva A, et 
al. 2006). The foreign DNA fragment, 
consisting of random oligomers, is inserted 
into the phage genome and the encoded 
foreign peptide is displayed on the surface of 
the phage as a fusion protein with one of the 
coat proteins. Fusion of the foreign peptide 
sequence is frequently done to the N-
terminus of the pIII and pVIII coat protein 
(Kehoe JW and Kay BK. 2005; Pande J, et al. 
2010). During the phage assembly process, 
the fusion proteins insert into the inner cell 
membrane of the bacterium along with the 
other phage proteins, and are incorporated 
into the nascent phage particle containing the 
ssDNA encoding the displayed fusion protein 
(Kehoe JW and Kay BK. 2005). 
 
The pIII coat protein is usually used with the 
cDNA libraries encoding proteins or protein 
domains as it tolerates the larger insertion 
better and has fewer copies than pVIII. 
Monovalent display may also be used in the 
case of large insertion in order to retain the 
coat protein function. In this approach, both 
fusion-proteins as well as wild-type proteins 
of the pIII are produced, thus forming a 
mosaic pattern of the pIII coat protein on the 
phage surface. In a hybrid display system, a 
phage genome carries both the wild-type and 
the fusion protein copies. Alternatively, a 
phagemid vector (i.e. a plasmid) is used to 
encode the fusion protein and a helper phage 
produces the wild-type protein as well as all 
the other proteins required for the phage to 
function. A polyvalent phage display – in 
which all the copies of the coat protein (such 
as pIII) display the foreign sequence – can be 
used with libraries containing short peptides 
that do not interfere with the function of the 
coat protein and thus the function of the 
phage. In general, polyvalent phage display 
provides higher avidity (i.e. higher binding 
strength) due to the higher number of peptide 
sequences displayed, and can therefore 
detect lower-affinity binding (Sergeeva A et al. 
2006). !
 
The most frequently used phage vectors to 
generate random peptide phage libraries are 
filamentous phage belonging to the Ff class 
(fd, f1 and M13). Several fusion-phage 
vectors with certain modifications to the 
phage’s wild type genome have been 
constructed for cloning purposes (Zacher AN 
et al. 1980; Parmley SF and Smith GP. 1988; 
Scott JK and Smith GP. 1990; Smith GP and 
Scott JK 1993). The first constructed phage 
vector was called fd-tet, which comprised of 
the wild-type fd genome and a segment of 
transposon Tn10 coding for tetracycline 
resistance (Zacher AN et al. 1980). 
Subsequently, many of the fusion-phage 
vectors, including the fUSE vectors and 
fAFF1, have been derived from fd-tet. 
Notably, these vectors have several 
advantages. For example, foreign inserts do 
not incapacitate the pIII protein significantly, 
and the phage remains capable of infecting 
the host cells as well as undergoing normal 
morphogenesis (Scott JK and Smith GP. 
1990). In addition, since the vector carries a 
tetracyclin selection marker and since 
filamentous phage do not kill their host, a 
single infection event is sufficient to produce 
a detectable tetracycline-resistant clone, 
which allows infective phage to be quantified 
as transducing units (TU), which measure 
bacteria colonies, rather than plaque-forming 
units, which measure regions of host cell 
destruction (Kehoe JW and Kay BK. 2005; 
Pande J, et al. 2010). 
 
However, the filamentous phage system also 
has some limitations, especially when trying 
to display proteins that do not fold properly in 
the periplasm (Kehoe JW and Kay BK. 2005). 
Consequently, alternative phage display 
systems using lytic bacteriophages – such as 
T4 (Jiang J, et al. 1997), T7 (Danner S and 
Belasco JG. 2001), and P4 (Catagnoli L, et al. 
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2001; Lindqvist BH and Naderi S. 1995) – 
have been developed, in which the capsid 
assembly occurs in the cytoplasm and the 
phage are released via cell lysis. 
Bacteriophage lambda is yet another vector 
system for the surface display of peptides 
and proteins (Sternberg N and Hoess RH. 
1995).  
 
4.5.3. Screening phage display random 
peptide libraries 
   
The advantages of phage display include the 
convenience with which libraries can be 
selected for target-specific binders via affinity 
purification. Notably, phage display typically 
enables identification of target-specific 
sequences with the affinity constants in the 
micromolar-to-nanomolar range. The phage 
clones that encode high-affinity polypeptides 
to the molecule or cell type under study are 
rapidly enriched by incubating the phage 
library with a target followed by removal of 
the non-binding phage and amplification of 
the high-affinity clone in the host bacteria. 
Usually, three to five rounds of biopanning 
are adequate to enrich for target-binding 
peptide sequences. Thus, the selection of 
target-specific sequences from a phage 
display library is a cyclic process involving 
selective enrichment and amplification.!
Subsequently, the primary structure of the 
high-affinity peptide displayed on the surface 
of the phage is determined by sequencing the 
corresponding encoding DNA (Sergeeva A, 
et al. 2006). Genomic tools have been 
integrated to make the process quick and 
affordable (Dias-Neto E, et al. 2009). 
 
Phage display has been routinely utilized in 
the in vitro setting to screen peptide or 
antibody libraries for ligands on purified and 
immobilized molecules (Kehoe JW and Kay 
BK. 2005). These applications have been 
useful in identification of protein-protein 
interaction pairs and mapping their interaction 
domains (e.g. Hertveldt K, et al. 2009; Voss 
M, et al. 2009; Samoylova TI, et al. 2006; 
Kolonin MG, et al. 2006a; Hartley O. 2002; 
Walter G et al. 2001; Romanov VI. 2003). In 
vitro screening has also yielded agents, 
including peptides specifically binding to 
caspases (Tamm I, et al. 2003), integrins 
(Koivunen E, et al. 1995; Cardó-Vila M, et al. 
2003), and metalloproteinases (Koivunen E, 
et al. 1999), that have been used in drug 
delivery approaches. 
 
Methods to screen phage libraries on 
cultured cells have also been developed (e.g. 
Barry MA, et al. 1996; Ivanenkov VV, et al. 
1999; Hong FD and Clayman GL 2000). One 
such method that enables isolation of specific 
ligands from a small amount of cells quickly 
and efficiently is the biopanning and rapid 
analysis of selective interactive ligands 
(BRASIL) method (Giordano RJ, et al. 2001).   
Examples of the successful phage display 
screening performed on cells include the 
identification of a peptide targeting vascular 
endothelial cells in gastric cancer (Liang S, et 
al. 2006) and a VEGF-mimic peptide 
targeting neuropilin 1 (NRP-1) and VEGFR-1 
(Giordano RJ, et al. 2005). In addition, the 
BRASIL method was used to systematically 
screen a combinatorial peptide library on 
tumor cells of the NCI-60 panel (Kolonin MG, 
et al. 2006a). During the selection for cell-
surface binders, each NCI-60 cell line was 
identified with a unique set of peptide motifs, 
reflecting on differently expressed receptors 
on their surface. Tumor cells were 
subsequently grouped based on these 
profiles. In essence, the ligand-directed 
surface profiling of tumor cell lines can 
facilitate the dissection of cancer cell surface 
proteome, thus providing information that 
could be exploited in search for “druggable” 
receptors against specific types of cancers.!
For example, epidermal growth factor 
receptor (EGFR), upregulated by many 
cancers, was validated as a target of a group 
of tripeptides mimicking the biological EGFR 
ligands (Kolonin MG, et al. 2006a). 
 
Furthermore, ex vivo protocols for selection 
and evaluation of phage display libraries on 
biopsy specimens have been evolved (Ardelt 
PU et al. 2003; Arap MA, et al. 2004, Shukla 
GS and Krag DN. 2005). For example, 
peptides binding to human breast tumor 
specimens have been identified in this 
fashion (Shukla GS and Krag DN. 2005). The 
advantage of the ex vivo phage display is that 
it allows the screening of the phage display 
peptide library on freshly obtained tumor 
specimens facilitating the identification of 
peptides that may bind to tumor-specific 
targets only under certain 
microenvironmental context. 
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Ultimately, in vivo phage display represents 
the most valuable tool to obtain 
physiologically relevant ligand-receptor pairs. 
The in vivo phage display enables the 
identification of peptide sequences homing to 
specific organs in an unbiased and internally 
controlled manner (Sergeeva A, et al. 2006), 
and ligands selectively homing to various 
tissues in mice have been selected via phage 
display screening (e.g. Pasqualini R and 
Ruoslahti E. 1996; Rajotte D, et al. 1998; 
Trepel M, et al. 2001; Samoylova TI and 
Smith BF. 1999; Arap W, et al. 2002a; 
Kolonin MG, et al. 2002; Kolonin MG, et al. 
2004; Kolonin MG, et al. 2006b; Liu JK et al. 
2014; Hyvönen M, et al. 2014). These tissue- 
and tumor-specific peptide motifs identified 
via in vivo phage display can serve as 
location signatures, often termed as “zip 
codes”, for these sites. Notably,! vascular 
addresses, which allow angiogenesis-related 
targeting of tumor blood vessels, have been 
identified via the in vivo phage display (e.g. 
Arap W, et al. 1998; Kolinin MG et al. 2001; 
Pasqualini R et al. 2000; Arap W, et al. 
2002a; Arap W et al 2002b; Joyce JA, et al. 
2003; Hoffman JA, et al. 2003; Marchió S, et 
al 2004; Kolonin MG, et al. 2006b).   
 
 
 
The information derived from animal studies, 
however, does not always translate into real 
clinical applications, mostly due to the 
species-specific differences in protein 
expression as well as protein structure.!
Consequently, in vivo phage display has also 
been performed directly in human, and 
peptides homing to specific organs were 
selected after systemic administration of a 
random peptide library to a brain-dead patient 
(Arap W, et al. 2002b). Appropriately, ethical 
framework for the in vivo phage display in 
human has also been established (Pentz RD, 
et al. 2003; Pentz RD and Flamm AL. 2003 & 
2005). The screening in human represents a 
significant improvement in the identification of 
clinically relevant targets via analysis of the 
distribution of combinatorial peptides in 
human tissue and subsequently identifying 
their corresponding receptors (Arap W, et al. 
2002b; Zurita AJ, et al. 2004). Notably, 
ligands that bind to receptors overexpressed 
in cancer have been identified, including the 
interleukin-11 mimic peptide and the 
interleukin-11 receptor (Zurita AJ, et al. 2004), 
along with the human leukocyte proteinase-3 
(PR-3) and receptor for advanced glycation 
end products (RAGE) (Staquicini FI, et al. 
2011).
 
 
 
Figure 3. Phage display technology. The principle of the phage display random peptide library screening is 
demonstrated via a flow chart. A basic structure of the filamentous phage, as well as different screening 
platforms are shown. 
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Aims of the study 
 
1. To elucidate the function of the proMMP-9 – M2-integrin complex in migration and 
growth of leukemia cells and to validate the therapeutic potential of peptides binding to 
this complex.  
 
2. To profile leukemia cell surface via phage display random peptide libraries and to identify 
new ligand-receptor pairs for targeted therapy. 
 
3. To study the role of IL-11R and NRP-1 as therapeutic targets in leukemia through 
expression analysis and functional assays.  
 
4. To develop and validate a novel ex vivo screening assay for the discovery of drug 
candidates against leukemia that are effective in the presence of human blood or bone 
marrow. 
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Results 
 
1. The pro-MMP9 – αMβ2 integrin complex 
as a functional target in extramedullary 
infiltration of AML 
 
1.1. Elucidation of the interaction between 
pro-MMP9 and αMβ2 integrin and 
identification of specific inhibitors of 
this complex 
 
The laboratory of Dr. Erkki Koivunen has 
previously shown that the proMMP-2 and 
proMMP-9 gelatinases bind to 2 integrins 
(Stefanidakis M, et al. 2004), and identified 
peptides that bind to the interfaces of this 
complex. In brief, a phage display random 
peptide library (a pool of CX7-10C and X9-10) 
was screened against the purified αM I 
domain of integrin that led to the identification 
of several peptides with a motif 
(D/E)(D/E)(G/L)W (Stefanidakis M, et al. 
2003). It was subsequently found via use of 
bioinformatic tools that these peptide 
sequences are naturally found in some of the 
known αM2 integrin ligands as well as in 
the catalytic domain of MMPs. 
Correspondingly, the peptide sequences 
sharing the (D/E)(D/E)(G/L)W motif were 
shown to mediate the binding between αM
2 integrin and proMMP-2 or proMMP-9 
(Stefanidakis M, et al. 2003). From these 
sequences, the ADGACILWMDDGWCGAAG 
(from here on referred to as DDGW) peptide 
was chosen for further studies as it showed 
the strongest binding to integrin (αM I 
domain) and was highly soluble in aqueous 
buffers (Stefanidakis M, et al. 2003). To 
further elucidate the interaction between αM
 2 integrin and proMMP-9, the whole 
proMMP-9 sequence was synthesized as 
overlapping 20-mer peptides on a pepspot 
membrane and binding of the αM I domain 
was assessed for each of these peptides 
individually. A single active peptide that 
located to the MMP-9 catalytic domain, 
QGDAHFDDDELWSLGKGVVV, was 
identified (Stefanidakis M, et al. 2003) that 
also contained the (D/E)(D/E)(G/L)W motif, 
which was initially selected via phage display. 
Additional screening by the pepspot system, 
by truncating the 20-mer to overlapping 
hexapeptides, identified that sufficient 
integrin-binding activity is achieved by the 
HFDDDE peptide (Stefanidakis M, et al. 
2004). Likewise, a novel small molecule, 
IMB-10, inhibiting the interaction between 2 
integrin and proMMP-9 was discovered by 
allowing a chemical library to compete with 
the binding of the phage displaying the 
DDGW peptide to αM I domain of integrin 
(Björklund M, et al. 2006).  
 
In this study, we sought to further elucidate 
the binding interaction between proMMP-9 
and αM2 integrins by using two separate 
truncated MMP-9 domains, (i) the proMMP-
9 domain containing the pro-domain and the 
catalytic domain that contains the collagen 
binding domain (Overall CM. 2002) 
composed of three fibronectin type II repeats, 
and (ii) the C-terminal hemopexin/vitronectin-
like domain (PEX), which contains the 
binding site for tissue inhibitors of MMPs 
(TIMPs) and is responsible of the 
dimerization of MMP-9 (Cha H, et al. 2002). 
Both of these domains were able to bind to 
OCI-AML3 cell surfaces (AML cell line), as 
shown by 125I-labeled MMP-9 domains, 
although proMMP-9 domain binding was 
more prominent (I, Fig. 6A). We showed that 
the cell surface binding of 125I-labeled 
proMMP-9 domain to OCI-AML3 cells was 
inhibited with specific M and L antibodies 
(namely TS1/22 and MEM170) as well as 
with soluble integrin I domain (I, Fig. 6B). 
Similar effects were observed with the 
peptides HFDDDE and DDGW, as well as 
CTTHWGFTLC, a peptide that targets the 
catalytic site of the MMP-9 (Koivunen E, et al. 
1999), but not with CRVYGPYLLC, a peptide 
that targets the hemopexin domain of MMP-9 
(Björklund M, et al. 2004)  (I, Fig. 6B). 
Moreover, the anti-MMP9 antibody generated 
against the sequence YQGDAHFDDDE 
(referred to as anti-HFDDDE), but not the IgG 
control, inhibited the  proMMP-9 domain 
binding (I, Fig. 6B). Conversely, the cell 
surface binding of 125I-labeled PEX-domain 
was inhibited by tissue inhibitor of 
metalloproteinase  (TIMP) – an endogenous 
MMP inhibitor – and the CRVYGPYLLC 
peptide, but not by proMMP-9 or Mβ2 
integrin targeting peptides, integrin antibodies, 
nor I domain (I, Fig. 6C). Genetic silencing of 
the M with siRNA provided further evidence 
that M2 integrin serves as the receptor 
for the proMMP9 domain (I, Fig. 6D & 6F). 
Furthermore, HFDDDE and DDGW peptides 
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that had been injected intravenously into 
Balb/C mice increased the serum levels of 
MMP-9, suggesting that both peptides 
prevent cell-surface binding of proMMP-9 
also in vivo (I, Fig. 4F). 
 
These results indicate that both the M2 
and  L  2 serve as receptors for 
proMMP-9 domain, but not for the PEX 
domain, and that this interaction is 
specifically inhibited by the agents targeting 
the proMMP-9 – β2 integrin complex, such as 
HFDDDE, DDGW, and IMB-10. 
 
1.2. The expression and co-localization of 
pro-MMP9 and β2 integrin in AML 
 
In the BRASIL assay (Giordano RJ et al. 
2001) phage displaying the DDGW peptide 
bound strongly to OCI-AML3 cells (I, Fig. 1A) 
as well as to bone marrow samples derived 
from AML patients (I, Fig. 1B), suggesting 
that the interaction between αM2 integrin 
and proMMP-9 also occurs in primary 
leukemia cells. Flow cytometry was used to 
assess the expression levels of both MMP-9 
and β2 integrin and its subunits. OCI-AML3 
cells were treated with phorbol ester, as 
stimulation of neutrophils by phorbol ester is 
known to induce the cell surface expression 
the proMMP9 – αMβ2 integrin complex 
(Stefanidakis M, et al. 2004). In addition, 
OCI-AML3 cells that had been grown in the 
presence of an endothelial cell monolayer 
showed higher levels of both MMP-9 as well 
as β2 integrin expression as compared to the 
cells grown in the absence of endothelial cell 
monolayer (I, Fig. 1E). Interestingly, the 
expression of αL integrin was relatively high 
on the cell surface even without stimulation, 
whereas the expression of αM was low and 
became detectable only after stimulation (I, 
Fig. 1E). Confocal microscopy was 
subsequently used to analyze the 
colocalization of MMP-9 and β2 integrin. 
Colocalization of proMMP-9 was detected 
with both αL and αM integrin subunits (I, Fig. 
1C). In addition, when OCI-AML3 cells were 
cocultured on top of an endothelial cell layer 
and stimulated with phorbol ester, the 
colocalization of proMMP-9 and αM  2 
integrin occurred in apparent contact areas 
between leukemia cells (I, Fig. 1D). 
 
These results suggest that the interaction 
between proMMP9 and αM2 integrin may 
also play a role in primary leukemia cells and 
that the complex appears to be concentrated 
at specific interaction sites upon stimulation 
of leukemia cells.  
 
1.3. Inhibition of the pro-MMP9 – αM2 
integrin complex exhibits anti-
leukemia activity 
 
The ability of DDGW peptide to recognize 
primary AML cells lead us to study the effects 
of the proMMP9 – αM2 integrin complex in 
xenograft murine models. When OCI-AML3 
cells were grown subcutaneously in nude 
mice, both the DDGW peptide and HFDDDE 
peptide, but not the corresponding control 
peptides, markedly decreased the growth of 
extramedullary leukemia  (I, Fig. 2A). The 
overall tumor volume was significantly 
reduces with both peptides. When mice were 
treated with the DDGW peptide the tumor 
response was significant for upto 20 days, 
however, with HFDDDE peptide, the tumor 
response was significant at early (20 days) 
and later (120 days) time points (I, Fig. 2B 
and 2C). Significant increase in actuarial 
survival was detected with both peptides (I, 
Fig. 2D and 2E). Markedly, discontinuation of 
the DDGW treatment, but not the HFDDDE 
treatment, resulted in leukemia regrowth. 
Neither of the peptides induces weigh loss or 
other adverse effects at the doses used. 
Similar results were obtained in nude mice 
bearing THP-1 xenografts (I, Fig. 3A). Anti-
leukemia activity of the proMMP9/αM 2 
integrin complex inhibitors, HFDDDE and 
IMB-10, was also observed in the long-term 
in vitro cultures of both OCI-AML3 cells and 
patient derived primary AML cells (I, Fig. 5E 
and 5F).   
 
1.4. Effects of the pro-MMP9 – β2 integrin 
complex inhibitors on extramedullary 
invasion and pericellular proteolysis of 
AML cells 
 
Next, we studied whether the inhibition of 
proMMP9 – αMβ2 integrin complex would 
affect transendothelial migration of OCI-
AML3 cells. Both the HFFDDE and DDGW 
peptides as well as the small molecule IMB-
10 inhibited the transmigration (I, Fig. 5A). 
Similar results were obtained in primary AML 
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samples with HFDDDE and IMB-10 in 
transmigration assay with collagen (I, Fig. 
5C). Moreover, small interfering RNA (siRNA) 
against αMβ2 and/or proMMP-9 significantly 
inhibited the transendothelial migration as 
compared to the control siRNA (I, Fig. 5B), 
suggesting that the complex may play an 
important role in extravasation. 
 
To obtain further evidence that the proMMP9 
– αMβ2 integrin complex is important for the 
extravasation of AML cells, we assessed 
whether the inhibition of the proMMP9 – 
αMβ2 integrin complex reduces the infiltration 
of leukemia cells to other commonly invaded 
extramedullary organ sites, such as liver and 
spleen in vivo. We studied the tissue 
distribution of the 125I-surface-labeled OCI-
AML3 cells (injected intravenously) with or 
without the HFDDDE and DDGW treatment in 
Balb/c mice. Treatment with both HFDDDE 
and DDGW caused an increase in cell pool 
remaining in the peripheral circulation (I, Fig. 
4A-C). Notably, HFDDDE was more active 
than DDGW, and HFDDDE significantly 
inhibited the accumulation of leukemia cells 
into bone marrow cavity, liver, and spleen (I, 
Fig. 4A). In addition, both DDGW and 
HFDDE inhibited leukemia cells infiltration to 
lungs (I, Fig. 4C) Moreover, a treatment with 
the anti-HFDDDE antibody resulted into 
similar outcome while the control IgG had no 
effect (I, Fig. 4D). 
 
Next, we sought to assess whether the 
inhibition of the proMMP9 – αMβ2 integrin 
complex also affects pericellular proteolysis. 
The HFDDDE peptide was shown to inhibit 
gelatinolysis as efficiently as the specific 
MMP-9 targeting peptides, CTTHWGFTLC 
and CRVYGPYLLC (I, Fig. 7A). Moreover, 
the endogenous cell surface proteins were 
biotinylated and their stability was assessed 
in the presence of the HFDDDE peptide and 
the control peptide DFEDHD. More 
biotinylated cell surface proteins were 
recovered from the cell cultures treated with 
the HFDDDE peptide compared with the 
DFEDHD peptide as shown via sodium 
dodecyl sulfate-polyacrylamide gel 
electrophoresis (I, Fig. 7B) as well as via 
streptavidin-phycoerythrin flow cytometry (I, 
Fig. 7C). Integrin 2 subunit was among the 
stabilized proteins with the HFDDDE 
treatment but not with the DFEDHD treatment 
(I, Fig. 7C). Similar results were obtained 
with the DDGW peptide (I, data not shown). 
Moreover, the degradation of [3H] proline-
labeled endothelial cell layer by OCI-AML3 
cells was inhibited by the HFDDDE peptide 
and the CTTHWGFTLC peptide as measured 
via release of the radioactive label (I, data 
not shown). The control peptides had no 
effects. 
 
These data show that the proMMP-9 – αMβ2 
integrin complex is required for both 
extravasation as well as for pericellular 
proteolysis, and that the inhibition of this 
complex decreases extramedullary infiltration 
and gelatinolysis. This results into increased 
numbers of circulating leukemia as well as 
increased stability of cell surface proteins. 
 
 
Figure 4. The invadosome complex and its 
peptide inhibitors. 
 
2. Cell surface profiling of leukemia cells 
via phage display random peptide 
libraries: NRP-1 and IL-11Rα  as potential 
therapeutic targets in leukemic bone 
marrow 
 
2.1. Identification of NRP-1 and IL-
11Rα  binding peptides  
 
We used phage display random peptide 
library (CX7C) for cell surface profiling of 
leukemia cells (MOLT-4) via BRASIL 
methodology (Giordano R, et al. 2001). 
Phage selection was performed with an 
excess of the competing Arg-Gly-Asp (RGD) 
synthetic integrin-binding peptide motif to 
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minimize and eliminate the recovery of RGD-
containing ligands (Christianson DR, et al. 
2007; Kolonin MG, et al. 2006a). Based on 
the enrichment of the clones in the samples, 
a new consensus motif Phe-Phe/Tyr-Any-
Leu-Arg-Ser (FF/YXLRS) was identified, which 
accounted for 22% frequency of the selected 
peptide sequences. Characteristic binding 
patter of one the FF/YXLRS peptide-displaying 
phages, specifically CGFYWLRSC peptide-
displaying phage, on different leukemia cell 
lines was further studied and the phage was 
shown to bind to all (n=8) the 
leukemia/lymphoma cell lines tested (II, Fig. 
1A). As the CGFYWLRSC peptide-displaying 
phage was internalized by leukemia cells (II, 
Fig. 1B), thus having a potential to be used in 
ligand-directed drug delivery approaches, we 
investigated it further.  
 
The similarity studies via online protein 
databases (NCBI, BLAST) revealed weak 
non-linear matches with proteins such as 
VEGF-165, plexin A1 and B1, all of which are 
known to interact with neuropilin-1 (NRP-1). 
We therefore tested the binding of 
CGFYWLRSC peptide-displaying phage with 
a recombinant NRP-1 protein, and found it to 
be significant. (II, Fig. 2A). Insertless phage 
as well as an unrelated peptide-displaying 
phage served as negative controls. In 
addition, when NRP-1 was specifically 
knocked-down in OCI-AML3 cells via RNAi, 
no binding of the CGFYWLRSC peptide-
displaying phage on these cells was 
observed, while the wild-type cells as well as 
the cells treated with the control siRNA 
maintained the binding of this phage (II, Fig. 
2E). These studies indicate that NRP-1 is a 
functional target of the CGFYWLRSC peptide 
sequence, and the enrichment of the 
CGFYWLRSC peptide-displaying phage on 
leukemia/lymphoma cells lines suggests that 
NRP-1 may be a promising candidate for 
targeted therapy approaches in leukemia. 
 
In another study, a cyclic phage-display 
random peptide library (CX7C) was 
intravenously injected to a brain-dead cancer 
patient (a 48-year old Caucasian male) who 
had previously been diagnosed with a B-cell 
malignancy (Waldenström 
macroglobulinemia) and treated via 
splenectomy, systemic chemotherapy, and 
immunotherapy (Pentz RD, et al. 2003 & 
2005; Arap W, et al. 2002b). The family 
members signed the informed consent for 
these studies. After 15 min infusion, tissue 
biopsies were collected, and phage was 
subsequently recovered and sequenced from 
the various tissues (Arap W, et al. 2002b). 
High-throughput pattern recognition analysis 
of the motif similarities were performed in 
order to find common sequences shared 
among multiple selected peptides in a target 
organ (Arap W, et al. 2002b). As expected, 
both ubiquitously binding motifs as well as 
organ specific motifs were identified. For 
instance, AGG was found to be a common 
tripeptide motif in prostate tissue. One of the 
selected peptides sharing this common motif 
was the GRRAGGS peptide that was found 
to mimic interleukin-11 (IL-11). Further 
studies validated that this IL-11 mimic peptide 
interacts with the IL-11 receptor alpha (IL-
11Rα), therefore confirming the GRRAGGS 
peptide and the IL-11Rα form a functional 
ligand-receptor pair (Arap W, et al. 2002b). 
The follow-up study showed that the 
GRRAGGS peptide mimicked a new 
functional protein-binding site within IL-11 
(Cardo-Vila M, et al. 2008).  
 
A study with a large cohort of human tissues 
revealed that the expression of IL-11Rα is 
increased in prostate cancer, particularly in 
metastatic prostate cancer, and in the 
associated vasculature (Zurita AJ, et al. 
2004). Furthermore, the subsequent work 
done by our group showed that IL-11Rα is 
strongly expressed by both tumor cells and 
tumor vasculature in human primary 
osteosarcoma and pulmonary metastasis, 
while no expression was observed in normal 
lung and bone marrow tissues (Lewis VO, et 
al. 2009). The potential of the CGRRAGGSC 
peptide to be utilized in targeted drug delivery 
approaches was also demonstrated by 
therapeutic targeting of prostate cancer via 
delivery of the pro-apoptotic peptide 
d(KLAKLAK)2 into the cells (Cardo-Vila M, et 
al. 2008; Zurita AJ, et al. 2004; Ellerby HM, et 
al. 1999) . 
 
Given the upregulation of IL-11Rα  in bone 
metastatic prostate cancer and osteosarcoma 
as well as the fact that the IL-11-mimic 
peptide was identified via screening a patient 
with B-cell malignancy, we hypothesized that 
IL-11Rα might also be expressed by 
leukemia cells.  
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2.2. Expression of NRP-1 and IL-11Rα  in 
leukemia cell lines and leukemic bone 
marrow 
To confirm the expression of NRP-1 on 
leukemia we studied the expression of these 
proteins on cell lines via flow cytometry. The 
expression of NRP-1 and IL-11Rα was 
confirmed in K562, OCI-AML3, and MOLT-4 
cell lines (II, Fig. 2B-D; III, Fig. 1A).  
 
Consistently with the result obtained in 
leukemia cell lines (II, Fig. 1A), the 
CGFYWLRSC peptide-displaying phage also 
bound to patient derived AML and ALL 
samples (II, Fig. 5A) suggesting that NRP-1 
is also expressed by primary leukemia cells. 
Immunohistochemistry (IHC) on formalin-
fixed, paraffin-embedded bone marrow 
samples from patient with AML and ALL 
confirmed the expression of NRP-1 in the 
patient derived ALL (n=6) and AML (n=24) 
bone marrow (II, Fig. 5B & C) while only a 
weak background expression was detected in 
bone marrow specimens from healthy donors 
(n=7) (II, Fig. 5B & C). A slightly higher NRP-
1 expression level was observed in ALL 
versus AML bone marrow samples (II, Fig. 
5B; Supplemental Fig. 1B). Similar 
discrepancy in expression levels of ALL 
versus AML was subsequently confirmed by 
others (Younan S, et al. 2012). Notably, the 
NRP-1 expression did not appear to be cell 
population specific, but rather was generally 
over-expressed in leukemic bone marrow (II, 
Supplemental Fig. 1), perhaps as a 
response to hypoxic microenvironment. 
Notably, bone marrow blast percentage was 
later shown to correlate with increased NRP-
1 expression, with the level being higher in 
those with bone marrow blast ≥90% (Younan 
S, et al. 2012).  
 
The cell surface expression of IL-11Rα was 
demonstrated via flow cytometry in a panel of 
leukemia and lymphoma cell lines (n=12) (III, 
Fig. 1A), as well as in different hematopoietic 
cells types derived from both healthy and 
leukemic tissues (III, Fig. 1B & 
Supplemental Fig. 1). All the leukemia and 
lymphoma cell lines tested stained positive. 
Also, the expression of IL-11R in a total cell 
population was increased in all the patient 
AML samples tested (3/3) compared to the 
normal bone marrow or peripheral blood from 
healthy donors (3/3) (III, Fig. 1B & 
Supplemental Fig. 1). Analysis of specific 
cell populations showed that IL-11R was 
mainly expressed on the surface of CD34+, 
CD33+ and CD14+ cells in the AML patient 
samples, with the exception of one sample 
staining positive also with the CD19+ cells (III, 
Fig. 1B & Supplemental Fig. 1). In addition, 
cell membrane expression of IL-11R was 
detected via cytospin analysis of purified 
CD34+ cells derived from patients with AML, 
where one out of two cases stained positive, 
and from healthy individuals, where both 
tested cases stained negative (III, 
Supplemental Fig. 2 & data not shown). 
 
Next, we studied the levels of IL-11R in 
formalin-fixed, paraffin-embedded bone 
marrow samples from AML patients (n=43) 
via IHC (III, Fig. 2 & Table 1). A strong 
expression was observed in a CLL bone 
marrow samples (n=2) (III, Fig. 2 & Table 1), 
which served as positive controls as the IL-
11R expression in CLL has already been 
reported (Tsimanis A et al. 2001). The 
leukemic bone marrow from AML patients 
had a significantly higher overall expression 
of IL-11R  , compared to normal bone 
marrow (Fisher s exact test, p=0.0448). 
Both leukemic blasts as well as vasculature 
contributed to the elevated expression levels, 
and over half of the leukemia blasts (23 of 43, 
53%), and practically all the evaluable blood 
vessels (16 of 17, 94%) – regardless of 
subtype and corresponding blast cell 
positivity – stained positively. Importantly, the 
normal vasculature from healthy bone 
marrow donors did not have detectable 
expression of IL-11R (Fishers exact test, 
p=0.0158). Specifically, 99% of the AML 
bone marrow samples tested had a 
significant disease involvement with more 
than 20% of white blood cells (WBCs) being 
leukemic blasts, and in most of the AML bone 
marrow samples tested (24 of 33), the 
disease involvement was higher than 40%, 
from which several cases (16) had over 60% 
blast percentage. In addition, evidence for the 
specificity of IL-11R  expression only in 
bone marrow specimens with significant 
disease involvement, was also obtained via 
staining the bone marrow samples with MDS 
with a partial disease involvement, where 
most of the tested cases (5 of 6) stained 
negative. Only two of these cases (cases 12 
& 13) had higher than 10% disease 
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involvement, and from these only one (case 
13) stained positive.  
 
Taken together, these results show that both 
NRP-1 and IL-11Rα are expressed in 
leukemia cell lines as well as in patient 
derived leukemic bone marrow samples. 
Thus both NRP-1 and IL-11Rα could 
potentially be utilized in targeted drug 
delivery approaches in leukemia. 
 
2.3. Targeted delivery of pro-apoptotic 
peptidomimetics to leukemia cells via 
NRP-1 and IL11Rα  binding peptides 
 
To assess the possibility of using NRP-1 and 
IL-11Rα as targets for systemic delivery of 
therapeutics into leukemic bone marrow, we 
evaluated the ability of NRP-1 and IL-11Rα 
binding peptides to serve as vehicles for 
targeted drug delivery.  
 
NRP-1 and IL-11Rα binding peptides were 
synthesized in tandem with a pro-apoptotic 
moiety, D(KLAKLAK)2 – an amphipathic 
peptidomimetic that induces apoptosis by 
physical interference and disruption 
mitochondrial membranes upon 
internalization by target cells (Ellerby HM, et 
al. 1999) – and the cytotoxic effect on 
malignant cells were studied in vitro. 
 
Relatively low concentrations (5 M - 30 
M range) of the NRP-1 targeting peptide, 
CGFYWLRSC-GG-D(KLAKLAK)2, were 
sufficient to significantly decreased cell 
viability in human leukemia and lymphoma 
cell lines, and in majority of cell lines the 
maximum inhibition was reached at ≤ 20 M 
(II, Fig. 3). The control peptides [an 
admixture of CGFYWLRSC + D(KLAKLAK)2] 
had no effect at equimolar concentrations. 
Similar results were obtained with patient 
derived leukemic bone marrow samples, 
although with slightly higher IC50 values (~30 
µM) (unpublished data, AACR Annual 
Meeting Abstract, 2012). In addition, no 
apparent cytotoxicity on mononuclear cells 
from normal bone marrow was observed with 
the CGFYWLRSC-GG-D(KLAKLAK)2 (upto 30 
µM) (unpublished data, AACR Annual 
Meeting Abstract, 2012).   
 
The IL-11Rα targeting peptide, 
CGRRAGGSC-GG-D(KLAKLAK)2, also 
decreased cell viability at relatively low 
concentrations (40 M - 100 M range) in 
human leukemia and lymphoma cell lines, 
and in most of the cases the maximum 
inhibition was reached at 60-80 M (III, Fig. 
3 & Supplemental Fig. 3). The control 
peptides [an admixture of CGRRAGGSC and 
D(KLAKLAK)2] had no effect at equimolar 
concentrations. Similarly, no apparent 
cytotoxicity on mononuclear cells from normal 
bone marrow was observer with the 
CGRRAGGSC-GG-D(KLAKLAK)2 peptide 
(upto 100 µM) (III, Fig. 4B).  
 
To further improve the drug efficacy of the 
BMTP-11 we designed and evaluated four 
analogs of this drug with modified structures 
through Merrifield synthesis and chemical 
lead-optimization (III, Supplemental Table 1). 
One derivative, BMTP-11 analog #4 (BMTP-
11A#4), which was myristoylated on its serine 
residue, showed an improved anti-leukemia 
activity as assessed via cell viability and 
proliferation assays with leukemia cell lines 
(III, Fig. 5A).  
 
Furthermore, the clonogenic potential of 
patient derived AML cells was assessed via 
methylcellulose assays and statistically 
significant inhibition was obtained at 100 M 
concentration for CGRRAGGSC-GG-
D(KLAKLAK)2 and at 30 M with the analog 
#4  (III, Fig. 5C), while the clonogenic 
potential of normal bone marrow cells from 
healthy individuals was not altered at 
equivalent concentrations (III, Fig. 5D). The 
concentrations used for these peptides in the 
clonogenic assay were selected based on 
their approximate maximal inhibition 
concentration values that were obtained via 
the cell viability and proliferation assay done 
with leukemia cell lines (III, Fig. 5A). 
 
The cells were further analyzed by AnnexinV 
and propidium iodide staining to assess the 
extent of cell death induced by the NRP-1 
targeting CGFYWLRSC-GG-D(KLAKLAK)2 
peptide as well as with the IL-11Rα targeting 
CGRRAGGSC-GG-D(KLAKLAK)2 peptide and 
its analog (II, Fig. 4; III Fig. 4D & 5B). The 
OCI-AML3 cells treated with 20 M of the 
CGFYWLRSC-GG-D(KLAKLAK)2 peptide for 
20 h had undergone a nearly complete cell 
death induction (> 95% of the cells) (II, 
Supplemental Table 1) while the cells 
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treated with the control peptides [an 
admixture of CGFYWLRSC + D(KLAKLAK)2 
at equimolar concentrations] had only 
background levels of cell death, which was 
similar to those observed in untreated control 
cells (4-6% of the cells) (II, Supplemental 
Table 1). The concentration-dependent cell 
death of OCI-AML3 cells was observed with 
the CGRRAGGSC-GG-D(KLAKLAK)2 after 
incubation for 20 h, and nearly a complete 
cell death induction was observed at 40 M 
or higher (>87 % of the cells), while the cells 
treated with the control peptides [an 
admixture of CGRRAGGSC and 
D(KLAKLAK)2 at equimolar concentrations] 
had only background levels of cell death, 
which was similar to those observed in 
untreated control cells (4-6% of the cells) (III, 
Fig. 3D).  
 
These data suggest a potential therapeutic 
window for our new drug candidates and 
confirm that they induce targeted cell death 
upon internalization into leukemia cells. Both 
of the drug candidates may thus have 
therapeutic utility in leukemia. 
 
3. Development and validation of a novel 
ex vivo screening assay for leukemia: 
Identification of new candidate drugs 
against leukemia 
3.1. Optimization of the ex vivo assay 
Stability and efficacy of a drug candidate can 
vary significantly depending on its 
microenvironment. Ex vivo models utilizing 
human tissue as a screening platform are 
therefore valuable preclinical tools as the 
species-specific disease microenvironment 
can be partially recapitulated. Thus, we 
rationalized that co-culturing leukemia cells 
with the components of their natural 
microenvironment, such as blood or bone 
marrow, would provide beneficial elements 
for a drug-screening assay. We searched for 
conditions where leukemia cells could 
proliferate in the presence of whole blood 
obtained from healthy volunteer donors. A 
dilution of 1:10 (vol/vol) of whole blood in a 
culture medium without serum was optimal 
for leukemia cell growth for 24 to 48 h. The 
oxygen level was set to 5%, to mimic the 
physiological partial pressure of oxygen in 
peripheral circulation. Several leukemia cell 
lines were tested (namely: K562, OCI-AML3, 
Molt-4, THP-1, Kasumi-1), and all of them 
were able to grow in these conditions. 
Interestingly, during the optimization, we 
noticed that leukemia cells induced the color 
of diluted blood medium to turn from bright 
scarlet red to dark red during an overnight 
incubation. Instead, the color change in the 
cultures without leukemia cells was not 
significant. Notably, the blood color switch 
from bright red to dark red was reversible 
when allowed to stay at normoxia (21% 
oxygen), and shaking accelerated the 
process. This suggested that leukemia cells 
depleted oxygen in the cultures faster than 
normal cells, causing a shift in hemoglobin’s 
oxygenation state. (IV, Fig.1). 
Time-dependent increase of white blood cell 
counts due to proliferation of leukemia cells 
(OCI-AML3 cells) in the blood-containing 
cultures was assessed via a blood count 
analyzer (IV, Fig. 2A). In addition, leukemia 
cell growth was assessed via three 
independent cell viability and proliferation 
assays, which measured (i) cellular lactate 
dehydrogenase activity, (ii) transfected 
luciferase activity, (iii) BrdU incorporation (IV, 
Fig. 2B-D). Leukemia cell growth above 
background became detectable after 
culturing for 20 h or longer. We used whole 
blood samples from more than 200 individual 
healthy donors, and all of them supported 
leukemia cell growth in these conditions.  
 
Since the color change of blood also served 
as a “built-in” indicator or leukemia cell 
viability in these cultures, we used 
hemoglobin’s absorption spectra to quantify 
the change in the oxygenation state. 
Measurement of absorbance at 600 nm (or 
optical density 600, OD600) was found to be 
optimal in these culture conditions, and the 
OD600 measurements were remarkably higher 
in blood medium with leukemia cells cultured 
in hypoxia versus normoxia after 40 h (IV, Fig. 
2E). Specifically, the OD600 of cultures 
without leukemia cells increased less than 
0.2 units after incubation for 40 h, while in the 
cultures with leukemia cells OD600 increased 
by 0.4 to 0.6 units (IV, Fig. 2E). Background 
levels, as determined by measuring the 
OD600 baseline levels at 0 h, varied only 
slightly (mean 1.8, range 1.7-1.9). Moreover, 
upon addition of oxygen to the leukemia-cell 
containing cultures, which had prior been 
grown under hypoxia for 20 h or more, the 
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blood’s color switched back to bright red and 
the OD600 values were practically identical 
with the oxygenated cultures grown under 
normoxia. These results indicated that 
leukemia cells were responsible of inducing 
the color change due to leukemia cells 
depleting the oxygen from the culture 
medium under hypoxic conditions. Notably, 
leukemia cell growth rate was similar in both 
hypoxic and normoxic conditions (IV, Fig. 2F), 
thus excluding the possibility that differences 
in cell growth rates per se were responsible 
of the color switch and higher OD600 values. 
In addition, we tested whether leukemia cell 
growth in human bone marrow aspirates from 
healthy donors is possible and whether we 
could detect the color change compared to 
control bone marrow cultures. We 
established that similar results to medium 
containing peripheral blood could be 
achieved in the cultures containing bone 
marrow (IV, Fig. 2G-I).  
 
To assess whether we could use this assay 
to detect an anti-leukemia activity, we studied 
the effects of etoposide – a topoisomerase II 
inhibitor known to be active against leukemia 
– and confirmed that sufficient window for 
detection existed (IV, Fig. 2J).   
 
The dependence of OD600 values on 
leukemia cell (OCI-AML3 cells) viability and 
growth was confirmed by correlating OD600 
values with WBC counts in two different 
donor blood samples in the presence and 
absence of many anti-leukemia compounds. 
Markedly, the blood count analyzer 
recognizes leukemic blasts as granulocytes 
and monocytes, respectively. In accordance, 
the most robust correlation with OD600 was 
observed with granulocytes (r=0.81 and 
r=0.79) and monocytes (r=0.66 and r=0.65) 
(IV, Fig. 3). In conclusion, the OD600 
measurement can thus be reliably used as an 
initial indicator of leukemia cell viability and/or 
growth.  
 
We used a large panel of individual whole 
blood samples (n>200) from healthy donors 
and all of them supported the growth of index 
leukemia cell lines (IV, data not shown). 
Under this short-term ex vivo assay 
conditions, we observed no detectable 
evidence of classical host versus graft 
reaction on the basis that neither the 
immunosuppressant cyclosporine A nor the 
immunostimulator interleukin-2 affected our 
results (IV, data not shown). However, one 
cannot entirely exclude the possibility that 
innate immune reactions could occur in the 
blood samples as leukemia cell growth may 
perhaps be retarded relative to standard in 
vitro culture conditions. Despite this technical 
caveat, human leukemia cells were able to 
overcome this potential obstacle and 
proliferate (IV, Fig. 2A-D). 
 
3.2. Screening of a small molecule 
compound library 
As a proof-of-concept, we screened a 
chemical library (size ~20,000) against 
human leukemia cells via the ex vivo assay. 
Specifically, we used the DIVERSetTM 
chemical library from ChemBridge, which 
provides a diverse collection of drug-like 
compounds for primary screening. We 
identified a total of 70 active compounds (“hit” 
rate of 0.35%) that decreased OD600 by at 
least 0.2 units (IV, data not shown). Further 
re-examination of an arbitrarily chosen subset 
of these compounds (n=20, equaling ~30% of 
the initial “hits”) revealed that 18 of 20 of 
compounds retained their anti-leukemia 
activity also in the absence of blood, and thus 
were reproducibly true positives, resulting 
into a hit-rate of 90% (18/20). 
 
The majority of the identified 70 compounds 
were novel and had not been previously 
published. Interestingly, however, some of 
the compounds selected were identical or 
structurally similar to compounds described in 
the literature, and many of these compounds 
were reported with potential anti-cancer, anti-
inflammatory, or anti-microbial activity (IV, 
data not shown). A few examples include 
N''-{4-[(4-bromo-2,3,5,6-
tetramethylbenzyl)oxy]-3-
methoxybenzylidene}carbonohydrazonic 
diamide hydrochloride, a compound 
that has been listed as an anti-prion agent 
(USPTO application #: 20100029773), which 
inhibits protein aggregation involved in 
diseases linked to protein aggregation and/or 
neurogenerative diseases, and 1-[2-(4-
biphenylyl)-2-oxoethyl]-2,6 
dimethylimidazo[1,2-a]pyridin-1-ium bromide, 
which has also been discovered by others via 
screening a chemical library for compounds 
with activity against the intracellular 
protozoan parasite Trypanosoma cruzi 
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(Bettiol E, et al. 2009). Moreover, 5-(2,4-
dihydroxybenzylidene)-2-(phenylimino)-1,3-
thiazolidin-4-one identified in this study is 
similar to 5-benzylidene-2-phenylimino-1,3-
thiazolidin-4-one (BPT) analogs, which have 
been reported to selectively induce apoptosis 
in cancer cell, independently of P-
glycoprotein status (Wu S, et al. 2006). In 
addition, three identified compounds were 
structurally similar to 1-(5-chloro-2-
methoxybenzoyl)-4-(3chlorophenyl) 
piperazine, which has been described as an 
anti-mitotic agent with anti-tumor activity 
(Weiderhold KN, et al. 2006). Moreover, 
certain structural moieties were common in 
the selected compounds, such as piperazine, 
hydrazide, and hydrazone derivatives. 
Interestingly, many piperazine derivatives are 
notable successful drugs, including the 
tyrosine kinase inhibitor Imatinib, used in the 
treatment of CML (Quintas-Cardama A, et al. 
2009). Hydrazone-based coupling methods 
have been used in medical biotechnology to 
couple drugs to targeted antibodies (Wu A 
and Senter PD. 2005). The hydrazone-based 
bond is stable at neutral pH in the blood, but 
is rapidly degraded in the acidic environment 
in lysosomes. In principle, the drug is thereby 
released inside the cell, where it exerts its 
function (Wu A and Senter PD. 2005).  
 
3.3. Validation of the discovered anti-
leukemia compounds 
To study the discovered compounds further, 
we selected four structurally different test 
compounds out of the 18 active compounds, 
namely #1, #2, #3, and #4. The activities of 
these compounds were detected, in addition 
to the OD600 measurement, in three different 
standard cell proliferation assay systems (IV. 
Fig. 4A), thus confirming that they were true 
anti-leukemia compounds. Structure-activity-
relationship studies were subsequently 
performed for each of these four compounds, 
with the criteria that the similarity of a parent 
compound to its analog should be at least 
50%. First, the compound analogs were 
screened in the ex vivo assay in the presence 
of blood to identify active analogs (IV, Fig. 
4B), and subsequently tested in the standard 
cell proliferation assays (IV, Fig. 5). Of the 
four identified test compounds and their 
active analogs, the compound #1 (N''{4
[(4bromo2,3,5,6tetramethylbenzyl)oxy] 
 3  methoxy-benzylidene} carbono -
hydrazonic diamide hydrochloride) and its 
analogs had the most robust anti-leukemia 
activity against the variety of leukemia and 
lymphoma cell lines tested in the standard 
culture conditions (IV, Fig. 5). This group of 
active carbonohydrazonic diamide-containing 
compounds (n=7) (IV, Fig. 6A) inhibited the 
increase both in OD600 and the leukemia cell 
counts, and all of them reduced the WBC 
counts to baseline levels at the 20 h time 
point with <0.05-0.001% probability (IV, Fig. 
6B). The activity of the compounds, with the 
exception of the compound #1A, decreased 
significantly after the 40 h incubation (IV, 
data not shown). All the compounds, with 
the exception of the compound #1B, were 
shown to efficiently induce cell death in 
leukemia cells (IV, Fig 6C). The compound 
#1N, which does not contain 
carbonohydrazonic diamide group in its 
structure, served as a negative control (IV, 
Fig. 6B & C). 
 
We next analyzed the effects of 
carbonohydrazonic diamide-containing 
compounds against different blood cell 
populations via the blood count analyzer at 0, 
20, and 40 h time points. The increase in the 
leukemia cell (OCI-AML3) population in the 
blood-containing medium was usually ~2 fold 
after a 40 h incubation, and the leukemic 
cells were detected as granulocytes and 
monocytes. Therefore, the compounds that 
showed activities against granulocytes and 
monocytes while lacking the effects on other 
cell population were thought to primarily 
target leukemia cells. Subsequent analysis of 
compound activities against normal blood 
samples lacking leukemia cells may further 
confirm the specificity towards leukemia cells, 
however, proper toxicity and safety studies 
are subsequently needed to validate these 
compounds. As an example, we show the 
activities of the most robust compound, the 
compound #1A, against different cell 
populations in the ex vivo assays (IV, Fig. 7A 
& B). We conclude that the compound #1A 
prevented the increase in WBC concentration 
both in the blood and bone marrow 
microenvironment albeit at different 
concentrations; and had no clear inhibitory 
effect against lymphocytes, RBCs, or plates 
(IV, Fig. 7A & B).  
 
Taken together, we showed as an example 
the initial validation of four arbitrarily selected 
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compounds that had been identified as “true 
hits”. From these four, the compound #1 and 
its analogs containing the carbonohydrazonic 
diamide group were the most effective 
inhibitors of leukemia cells both in the 
presence and absence of blood. Markedly, 
the analogues, which lacked the 
carbonohydrazonic diamide, were inactive in 
the presence of blood. These results indicate 
that carbonohydrazonic diamide is required 
(Fisher’s exact test, p=0.0217) for the anti-
leukemia activity of this class of compounds. 
 
3.4. The effects of carbonohydrazonic 
diamine-containing compounds on 
primary AML cells.  
 
To validate the ex vivo assay in the context of 
patient samples, we assessed whether the 
increase in OD600 was affected by the initial 
cell counts, and observed that the measured 
OD600 values were increased in the presence 
of high blast counts (IV, Fig. 8A). In addition, 
mononuclear WBCs from the peripheral 
blood of AML patients were isolated and then 
re-inserted into the ex vivo cultures at 
concentrations which enriched the WBCs 
(including blasts) ~2-fold. Doubling of the 
WBC count resulted in a corresponding 
increase in the OD600, and the higher OD600 
values were observed with samples 
containing higher blast counts (IV, Fig. 8D). 
These results indicated that the leukemia 
blast counts were the major contributor to the 
OD600 values and that this culturing method 
could also be used with patient samples.  
 
To test the efficacy of the drug candidates in 
patient samples, we tested the activities of 
the carbonohydrazonic diamide-containing 
compounds in the presence of peripheral 
blood obtained from AML patients. Many of 
the carbonohydrazonic diamide-containing 
compounds proved to be active also in the 
patient sample setting (IV, Fig 8A). Certain 
compounds (namely: #1, #1C, and #1E) had 
different efficacies depending on the patient 
sample tested, indicating that individual 
testing of each patient may be required to 
identify the best drug candidates for each 
patient. To confirm that the effects of the 
carbonohydrazonic diamide-containing 
compounds are specific to leukemia cells, we 
assessed the activities of carbonohydrazonic 
diamide-containing compounds in the 
presence of normal blood from healthy 
donors. In two of three normal blood samples 
the compounds had no statistically significant 
effects but in the third sample the compound 
#1A reduced the OD600 slightly, suggesting 
individual-specific differences in susceptibility 
(Fig. 8C).  
 
 
  
Figure 5. An example 
screening plate. Leukemia 
cell viability in a human blood-
containing assay is monitored 
via oxygen consumption of 
leukemic cells, which is 
observed as a color change 
under hypoxic conditions due 
to depletion of oxygen from 
hemoglobin. Each well 
contains a different test 
compound, and the inhibition 
of color change from bright 
red to dark red indicates that 
the compound may have 
effective activity against 
leukemia. 
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Discussion 
 
1. Identification of new ligand-receptor 
pairs via phage display technology for 
therapeutic targeting of leukemia (I-III) 
 
Phage display random peptide libraries offer 
a high-throughput screening platform for 
identification of ligand mimics that selectively 
bind to cell surface markers. These target-
specific binders can subsequently be utilized 
for ligand-directed drug delivery. For example, 
several ligand mimics that recognize 
receptors in the cell surface of lymphoma and 
leukemia cell lines have been reported (e.g. 
Binder M, et al. 2011; Jäger S, et al. 2007; 
McGuire MJ, et al. 2006; Takahaski S, et al. 
2003; Koivunen E, et al. 2001). Importantly, 
many of the selected peptide ligands are 
internalized by cells and may thus be 
applicable for ligand-directed drug delivery. 
For instance, it has been demonstrated that 
pro-apoptotic peptides guided by the ligand 
mimics selected by phage display screening 
against tumor cell surface molecules may be 
exploited as “drug carriers” that target 
receptors in specific types of cancer and 
subsequently deliver the drug inside the cell 
(Nishimura S, et al. 2008; Kolonin MG, et al. 
2006a; Zurita A, et al. 2004; Arap M, et al. 
2004). Successful development of ligand-
directed therapeutic targeting requires a 
thorough evaluation of the candidate ligand-
receptor pairs in the context of the disease. In 
the work presented here, we report three new 
leukemia-specific ligand-receptor pairs 
discovered using the phage display 
technology, and evaluate their therapeutic 
potential. Specifically, we identified three new 
peptide motifs that bind to (i) a αL/αMβ2 
integrin - pro-MMP9 complex (termed: the 
invadosome complex), (ii) NRP-1, and (iii) IL-
11Rα.  
 
1.1. Targeting the invadosome complex 
 
The expression of matrix metalloproteinases 
(MMPs) is increased in several cancers and 
MMPs are associated in cancer-related 
processes such as invasion, angiogenesis, 
and inflammation (Hatfield KJ, et al. 2010). 
However, the broad-spectrum MMP inhibitors 
have not been very successful in clinical trials 
(Shi Z-G, et al. 2012). Instead, new 
approaches with more specific mechanisms 
to target individual MMPs are needed, and 
selective inhibition of the cell surface 
associations of individual MMPs, while not 
interfering with their catalytic activity, offers 
superior means to target these enzymes. 
 
For instance, MMP-2 and -9 are known to 
associate with the cell surface, and directly 
influence cell behavior as well as activate the 
signaling pathways involved in many 
biological events such as cell growth, 
migration and survival (Bauvois B. 2012). Cell 
surface associations of proteases provide a 
straightforward mechanism by which cells 
may direct the proteolytic activity at the right 
location, greatly controlling cell migration and 
invasion (Björklund M and Koivunen E. 2005).  
 
Multiple interaction mechanisms of MMP-2 
and -9 on the cell surface have been 
identified. For example, MMP-9 binds with 
the membrane-associated form of the DNA 
repair protein Ku in AML cells (Monferran S, 
et al. 2004), and the interaction was shown to 
inhibit migration and invasion of leukemia 
cells (Monferran S, et al. 2004). In murine 
mammary carcinoma cells, it has been shown 
that CD44 provides a cell surface docking 
site for proteolytically active MMP-9, and that 
this interaction promotes tumor invasion and 
angiogenesis as well as cleaves latent TGF-
 (Yu Q and Stamenkovic I. 2000). Similarly, 
MMP-9 binds with the 41 integrin and 
CD44 on the surface of B-cell lymphoma 
(Redondo-Munoz J, et al. 2008), which was 
shown to lead to Lyn kinase activation, 
STAT3 phosphorylation and up-regulated 
expression of the pro-survival protein Mcl-1 
(a BCL-2 family member) (Redondo-Munoz J, 
et al. 2010). It has also been shown that the 
association of MMP-9 with CD44 activates 
the tyrosine kinase EGFR signaling pathways, 
and subsequently promotes cell migration 
(Dufour A, et al. 2010). Moreover, in lung 
cancer cells, binding of MMP-9 to V3 
integrin has been shown to induce PI3K/AKT-
mediated VEGF expression and related 
angiogenesis (Chetty C, et al. 2010).  
 
A specific association of MMP-2 and MMP-9 
with cell surface integrins L2 and M2 
has also been reported, and shown to affect 
the motility of leukocytes (Stefanidakis M, et 
al. 2004). While the L2 integrin (also 
known as lymphocyte function-associated 
antigen 1) is expressed on all the leukocytes, 
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the  M  2 integrin (also known as 
macrophage 1 antigen) is expressed on the 
surface of innate immune system leukocytes 
such as monocytes, macrophages, 
granulocytes, and natural killer cells. 
Importantly, the inhibition of the interaction 
between  L/  M  2 and proMMP-9 
appeared to be specific to the leukocytes 
forming the complex, and does not interfere 
with the catalytic MMP-9 and MMP-2 activity 
in the other cell types. Interestingly, bone 
marrow-derived myelomonocytic cells that 
were double positive for M2 integrin and 
MMP-9 were reported to be major 
contributors to tumor development and 
vasculogenesis in MMP-9 knockout mice 
receiving wild-type bone marrow (Ahn G-O 
and Brown JM. 2008).  
 
In the present study, we show that the 
HFDDDE peptide, which inhibits the 
proMMP-9 – M2 integrin complex via 
competing with proMMP-9 of the integrin 
binding site, inhibited the leukemia cell 
migration through endothelial cell layer in 
vitro. Accordingly, the extravasation of 
leukemia cells that had been injected 
intravenously into mice was inhibited by the 
HFDDDE peptide, resulting into a significant 
reduction of leukemia cell burden in many 
organs including lung, spleen, liver, and bone 
marrow. In addition, HFDDDE peptide 
reduced tumor growth in vivo. These data 
show that the proMMP-9 – M2 integrin 
complex is important for the migration and 
growth of leukemia cells, and the inhibition of 
this interaction may have therapeutic 
implications.  
 
We also show that the HFDDDE peptide 
inhibited pericellular proteolysis as efficiently 
as other previously reported specific 
gelatinase-inhibiting peptides CTTHWGFTLC 
and CRVYGPYLLC (Björklund M, et al. 2004). 
Interestingly, the  2 integrin chain was 
stabilized by the HFDDDE treatment, 
suggesting that MMP-9 may also exert 
protelytic activity on its integrin binding 
partner. This phenomena, could also explain 
the low cell surface expression of M2 
integrin on OCI-AML3 cells as observed via 
flow cytometry. Consistently, others have 
shown that the 2 integrin subunit is cleaved 
and shed by MMP-9 and that M2 integrin 
is a substrate for MMP-9 (Vaisar T, et al. 
2009). The steady degradation of  2 
integrins may be relevant for mobility and 
generation of new adhesion sites, and similar 
proteolytic activity may be required not only 
for extramedullary infiltration but also within 
bone marrow.  
 
Association of MMP-9 with its M2 / L
2 integrin partners occurs via two main 
mechanism. The I domain interacts with the 
MMP-9 catalytic domain, while the  2 
subunit interaction occurs with the C-terminal 
PEX domain and appears to dynamically 
mediate MMP9 activation and pericellular 
gelatinolysis (Björklund M, et al. 2004). It is 
possible that these two different interaction 
mechanisms between integrin   and  
subunit and distinct MMP-9 domains 
complement each other; for instance by 
regulating localized proteolysis by directing 
MMP-9 activity where it is needed. Therefore, 
inhibition of the PEX domain of MMP-9 may 
also be required for the efficient anti-tumor 
effect. Future studies are needed to elucidate 
these points. As such, targeting the 
interactions between proMMP-9 and M2 
integrin as well as the PEX domain and its 
binding partners may be viable approaches to 
inhibit MMP-9-mediated functions. 
 
Taken together, the agents targeting the 
proMMP-9 – L/M2 integrin complex 
have a potent anti-leukemia effect and may 
have therapeutic utility in the extramedullary 
phenotype of AML. The inhibition of the 
invadosome complex may also be useful for 
anti-inflammatory effects, as well as for 
inhibiting bone marrow derived tumor-
infiltrating myelomonocytes in solid tumors. 
However, whether the inhibition of these 
complexes also interferes with the anti-tumor 
immune effects needs to be determined. 
 
1.2. Targeting NRP-1 
 
NRP-1 is a transmembrane glycoprotein with 
a large extracellular domain that interacts 
with some members of the VEGF ligand 
family, namely VEGF165, VEGF-B, VEGF-E, 
and placental growth factor (Klagsbrun M, et 
al. 2002), as well as with class 3 
semaphorins, a family of secreted 
polypeptides with key roles in axonal 
guidance (He Z and Tessier-Lavigne M. 
1997; Kolodkin AL, et al. 1997). NRP-1 is 
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mainly expressed by neurons and endothelial 
cell (Staton CA, et al. 2007) and it has an 
essential role during normal vascular and 
neuronal development (Kawakami A, et al. 
1996; Herzog Y, et al. 2001; Gu C, et la. 
2003) by acting as a coreceptor with VEGFR 
and plexins, the transmembrane receptors of 
the semaphoring family (Takahaski T, et al. 
1999; Neufeld G, et al. 2002). In addition, 
NRP-1 has been shown to interact with a 
number of heparin-binding growth factors 
(West DC, et al. 2005), as well as to be a 
mediator in the primary immune responses 
(Wulfing C and Rupp F. 2002; Trodjman R, et 
al. 2002), and up-regulation of the NRP-1 
expression is achieved as a response to 
tissue injury or hypoxic conditions 
(Brusselmans K, et al. 2005; Matthies AM, et 
al. 2002). NRP-1 is highly expressed in 
diverse solid tumors and increased 
expression of NRP-1 has been correlated 
with tumor growth and vascularization in vivo 
and with invasiveness in human cancer (Pan 
Q, et al. 2007; Hansel DE, et al. 2004; Latil A, 
et al. 2000; Bachelder RE, et al. 2001). 
Furthermore, beyond its role during normal 
vascular and neuronal development and 
tissue repair, NRP-1 expression has also 
been reported in placenta and heart in normal 
adult tissues (Soker S, et al. 1998). However, 
targeting of NRP-1 in vivo seems to be an 
appropriate approach for cancer therapies as 
indicated by studies with mouse models 
(Sugahara KN, et al. 2010; Teesalu T, et al. 
2009). This may be due to the generally high 
NRP-1 expression in cancer cells compared 
to normal tissue, thus resulting in preferential 
homing of the targeting peptide into tumors.  
 
Correspondingly, the increased 
anagiogenesis and expression of NRP-1 in 
CML and AML patients have been reported 
(Padró T, et al. 2000; Hussong JW, et al. 
2000; Vales A, et al. 2007; Yamada Y, et al. 
2003). In the present study, we found that the 
CGFYWLRSC phage binding to bone marrow 
samples derived from leukemia patients 
correlated with cell-surface expression levels 
of NRP-1. In addition, the NRP-1 expression 
was significantly higher in the bone marrow 
samples obtained from patients with ALL and 
AML as compared to normal bone marrow 
samples obtained from healthy donors. In 
addition, we noticed that bone marrow 
samples from ALL patients showed a slightly 
higher median expression level of NRP-1 
than samples from AML patients, suggesting 
that NRP-1 expression might be elevated in 
ALL as compared to AML. Others have 
subsequently obtained similar results, 
confirming that NRP-1 expression is higher in 
leukemic bone marrow versus normal bone 
marrow, as well as in ALL versus AML bone 
marrow (Younan S, et al. 2012). To study the 
expression pattern of NRP-1 in more detail, 
we analyzed the NRP-1 levels at the cell 
population level and noticed that NRP-1 
expression was increased in several different 
cell populations obtained from leukemic bone 
marrow. Thus, NRP-1 appeared to be 
expressed generally in leukemic bone 
marrow. As leukemia progresses and 
leukemia blast numbers increase, the bone 
marrow microenvironment becomes more 
hypoxic. Increased hypoxia is known to 
promote VEGF as well as NRP-1 expression, 
leading to increased cell survival 
(Brusselmans K, et al. 2005). Accordingly, 
NRP-1 expression levels have been reported 
to significantly correlate with the blast 
percentage higher than 90% in both AML and 
ALL (Younan S, et al. 2012). Also, another 
study showed that NRP-1 expression 
correlated with the percentage of blasts both 
in peripheral blood and bone marrow of AML 
patients (Lu L, et al. 2008). It is therefore 
feasible that the increased NRP-1 expression 
correlates with the disease progression in 
leukemic bone marrow, similarly as reported 
in invasive solid tumors, in which NRP-1 
staining increases progressively in intensity 
and area of expression during histological 
progression from low-grade to high-grade 
lesions (Hansel, DE. et al. 2004). Markedly, 
Younan et al. showed that NRP-1 expression 
was diminished in the ALL and AML patients 
who had undergone a CR as compared to the 
prevalent high levels in the patients who did 
not go into CR (Younan S, et al. 2012), 
suggesting that NRP-1 levels might in fact 
serve as an indicator for disease progression 
and severity. Similarly, in vivo administration 
of VEGF was able to induce AML progression 
in a systemic mouse model, whereas a 
soluble form of NRP-1 significantly inhibited 
this progression (Schuch G, et al. 2002). In 
addition, increased NRP-1 expression has 
been reported to correlate with poor survival 
in AML patients (Kreuter M, et al. 2006). 
Taken together, these results indicate that 
NRP-1 is a valid target in leukemia, and that 
the NRP-1 levels correlate with the disease 
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progression and severity.  
We next evaluated the drug delivery potential 
of the novel NRP-1-binding sequence 
CGFYWLRSC. In order to study the cytotoxic 
effect of NRP-1 targeting against leukemia 
cells in vitro, we synthesized the 
CGFYWLRSC peptide in tandem to a pro-
apoptotic moiety, D(KLAKLAK)2, which is an 
amphipathic peptidomimetic that induces 
apoptosis by physical disruption of 
mitochondrial membranes upon 
internalization by target cells (Ellerby HM, et 
al. 1999). Importantly, D(KLAKLAK)2 is not 
able to penetrate into cells on its own and 
requires an appropriate drug delivery system 
in order to internalize into the cells and 
induce apoptosis. In fact, our results show 
that both leukemia and lymphoma cell 
viability was inhibited by using the 
CGFYWLRSC-GG-D(KLAKLAK)2 peptide – in 
which the glycinylglycine (Gly-Gly) linker was 
added as a spacer to prevent steric 
hindrance – while D(KLAKLAK)2 alone did not 
have such an effect. Moreover, we did not 
detect any effect on leukemia cells when the 
CGFYWLRSC peptide was used alone, 
indicating that the targeting peptide itself did 
not have any intrinsic anti-tumor activity. On 
the contrary, another NRP-1 binding peptide 
reported by others has been shown to induce 
apoptosis on its own (Barr MP, et al. 2005). 
The advantage of the CGFYWLRSC peptide 
is, however, that it can be used with several 
different cytotoxic drug candidates, 
(KLAKLAK)2 being just an example, thus 
leaving room for adjustments if any adverse 
effects were to be obtained with a particular 
drug candidate. For instance, our ongoing 
independent pre-clinical studies on 
(KLAKLAK)2 have shown that the renal 
clearance of D-residues from the 
D(KLAKLAK)2 motif is a dose-limiting factor 
due to nephrotoxicity, however, this toxicity is 
reversible and is unrelated to the specific 
targeting peptide (Pasqualini R, et al. 2015). 
In addition, this new ligand-receptor 
interaction between NRP-1 and the 
CGFYWLRSC peptide can also be utilized in 
other drug delivery systems targeting human 
leukemia. Furthermore, others have recently 
reported that NRP-1 mediated internalization 
of peptides is dependent on a C-terminally 
exposed arginine (or infrequently lysine) 
residue with a R/KXXR/K motif (Teesalu T, et al. 
2009; Sugahara KN, et al. 2010). However, 
the CGFYWLRSC peptide does not contain 
such a motif. Our peptide also does not 
contain another identified polybasic NRP-1-
binding motif, RRXR, likewise selected by 
phage display (Hong TM, et al. 2007), and is 
distinct from the other known phage-display-
derived peptides that bind to NRP-1 
(Giordano RJ, et al. 2005; Giodano RJ, et al. 
2010; Giodano RJ, et al. 2001). These 
discrepancies suggest that the CGFYWLRSC 
peptide may interact with a different NRP-1 
binding site than the other described NRP-1 
binding peptides. 
 
Taken together, NRP-1 is a promising target 
in leukemia and lymphoma, and it can be 
utilized for ligand-directed drug delivery. The 
NRP-1 binding peptide, CGFYWLRSC in 
conjunction with a drug candidate may be 
used for therapeutic targeting of human 
leukemia and lymphoma. In addition, the 
NRP-1-binding motif, FF/YXLRS offers a 
promising candidate for lead optimization and 
targeted drug development. Ultimately, future 
studies will be needed to address the 
capability of this new NRP-1 binding peptide 
motif to facilitate targeted drug delivery in 
vivo.  
 
1.3. Targeting IL-11R  
 
Many organ-specific molecules are 
expressed in restricted locations that may not 
be accessible for therapeutic targeting via 
circulation. In vivo phage display offers an 
alternative means to profile human tissue and 
obtain target-specific ligand-mimics that bind 
to receptors accessible via vasculature. 
Utilizing this technology by injecting a phage 
library into a brain-dead cancer patient, we 
have previously identified a tumor-targeting 
IL-11 ligand mimic that was demonstrated to 
target IL-11Rα. We subsequently showed 
that IL-11Rα is upregulated in bone 
metastatic prostate cancer (Zurita AJ, et al. 
2004) and in osteosarcomas (Lewis VO, et al. 
2009), – both which share a bone marrow 
microenvironment – but not in healthy tissues, 
including bone marrow (Lewis VO, et al. 
2009; Zurita AJ, et al. 2004), and successful 
outcomes were obtained in therapeutic 
targeting of IL-11Rα in metastatic prostate 
cancer (Zurita AJ, et al. 2004). We therefore 
rationalized that the IL-11Rα could also be a 
potential target for therapeutic intervention in 
leukemia. 
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Support to this hypothesis also comes from 
several studies by others, which have 
reported high expression of the IL-11Rα in 
different leukemia subtypes, particularly in 
AML-M5 blast cells and in B-CLL, thus 
suggesting that IL-11Rα may play a role in 
the pathogenesis of leukemia (Kimura T, et al. 
1999; Tsimanis A, et al. 2001; Cherel M, et al. 
1995). For example, it was shown that AML 
cells, in particular those from M5 subtype 
expressing high levels of IL-11R, exhibited 
enhanced clonal proliferation in response to 
co-stimulation by IL-11 and G-CSF (Kimura T, 
et al.  1999). Another study demonstrated 
that the expression level of IL-11R is much 
higher in B-cell chronic lymphocytic leukemia 
cells (B-CLL) as compared to peripheral 
blood lymphocytes from healthy donors 
(Tsimanis A, et al. 2001). The study also 
showed that the recombinant human IL-11 
activates B-CLLs resulting in morphological 
changes and increased cell proliferation, 
which suggest that IL-11R and its natural 
ligand might be implicated in the 
pathogenesis of malignant B-CLL (Tsimanis 
A, et al. 2001). In addition, IL-11R  
transcript expression has been reported in 
the CML cell line K562, the megakaryocyte 
cell line Mo7E, and the erythroleukemia cell 
line TF1 (Cherel M, et al. 1995). Moreover, 
IL-11 signaling has recently been reported to 
enhance HSC and MPP radioresistance as 
well as facilitate their recovery from 
irradiation, subsequently leading to radiation-
induced B-cell malignancies (Louria-Hayon I, 
et al. 2013). These data support the idea that 
IL-11R   may be a suitable target for 
leukemia therapies. 
 
In this this study, we evaluate the expression 
and therapeutic targeting potential of IL-
11Rα in the context of human leukemia, with 
the emphasis on AML. Our results show that 
IL-11R  is highly expressed in various 
leukemia cell lines and that the ligand-
directed proapoptotic peptidomimetic, 
CGRRAGGSC-GG-D(KLAKLAK)2 that targets 
IL-11Rα, significantly reduces leukemia cell 
viability. Moreover, this peptide exhibited 
significantly lower toxicity on normal 
lymphocytes, neutrophils, and monocytes as 
compared to Molt-4 leukemia cells. Similarly, 
no toxicity was observed with mononuclear 
cells isolated from healthy bone marrow. We 
also show that IL-11R   is moderately 
expressed in most of the tested bone marrow 
samples from AML patients.  
 
Downstream effectors of the IL-11/IL-11R 
signaling pathway include receptor-
associated JAKs and STATs, which promote 
cell survival, proliferation, invasion, 
angiogenesis, metastasis, as well as immune 
responses associated with inflammatory 
diseases and tumor progression. IL-11/IL-
11R signaling is known to modulate several 
biological activities, including hematopoiesis 
and lymphopoiesis. It has been reported that 
low levels of IL-11 messenger RNA are found 
ubiquitously, although, the IL-11 protein is 
rarely detected in the serum of healthy 
subjects whereas a pathological stimuli such 
as viral inflammation or many cancers can 
induce IL-11 expression (Putoczki T and 
Ernst M. 2010; Schwertschlag US, et al. 
1999). 
 
Despite the roles of IL-11 during normal 
biological processes it was previously shown 
that mice lacking the IL-11R gene display 
normal phenotype (Nandurkar HH, et al. 
1997). Accordingly, our clinical trial study 
shows that the CGRRAGGSC-GG-
D(KLAKLAK)2 peptide systemically targets 
metastatic prostate cancer via targeting the 
IL-11Rα, without inducing any persistent 
adverse effects (Pasqualini R, et al. 2015). 
Markedly, we have previously shown that 
although the CGRRAGGSC peptide mimics 
the IL-11 ligand, the corresponding location 
within the native cytokine is not in a 
characterized interaction site between IL-11 
and IL-11R; therefore establishing a new 
interaction mechanism with the IL-11R 
receptor (Cardó-Vila M, et al. 2008). This 
might, in part, contribute to specific tumor 
targeting attributes of this peptide. As 
prostate cancer that has metastasized to 
bone shares a similar microenvironment as 
leukemia, it is probable that the 
CGRRAGGSC-GG-D(KLAKLAK)2 peptide 
exerts similar specific targeting effects also in 
the context of leukemia. 
 
Given the successful clinical outcomes with 
therapies in bone metastatic prostate cancer 
patients, we initiated the lead optimization 
efforts for the CGRRAGGSC-GG-
D(KLAKLAK)2 peptide in order to find an 
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analogue with a superior efficacy profile. To 
improve its pharmacokinetics, some of the 
residues where introduced in their d-amino 
acid forms to the peptide sequence. However, 
these modifications did not improve the anti-
cancer activities of the peptide in vitro. 
Myristoylation of the serine residue, on the 
contrary, increased the activity significantly in 
the in vitro cultures of both cell lines as well 
as patient derived primary AML cells. The 
myristoyl group is highly lipophilic, which 
enables its incorporation into the 
phospholipid bilayer of cell membranes, and 
is likely used to facilitate the internalization of 
the peptide. In effect, N-myristoylation 
enables the association and binding of many 
proteins with cell membranes (Farazi TA, et 
al. 2001). Typically, myristate helps to 
regulate protein targeting, function, and 
interaction with cell membranes by serving as 
a lipid anchor in cell membranes for 
myristoylated peptides (Farazi TA, et al. 
2001). For example, N-myristoylated phorbol 
ester protein kinase C-   (PKC-  ) 
pseudosubstrate peptides potently induced 
an uptake of chemotherapeutic drugs by 
human colon cancer cells through a P-
glycoprotein-independent mechanism 
(Bergman PJ, et al. 1997). In our study, the 
CGRRAGGSC-GG-D(KLAKLAK)2 also 
achieved improved internalization abilities 
upon myristoylation of its serine residue as 
indicated by the induction of apoptosis at 
earlier time points compared to the original 
unmyristoylated peptide. Myristoylation of the 
peptide also improved its efficacy against 
primary AML cell samples. 
 
Markedly, IL-11 has been reported to play a 
role in recruiting dormant/quiescent leukemic 
progenitors into the cell cycle (Kimura T, et al. 
1999). Accordingly, we have previously 
shown that the CGRRAGGSC peptide 
induces STAT3 phosphorylation in TF-1 cells 
(Cardó-Vila M, et al. 2008), in which STAT3 
is not constitutively activated naturally, 
suggesting that IL-11R  may serve as a 
target that activates quiescent cells thus 
rendering them susceptible to therapies. In 
contrast to the studies by others, where 
leukemia cell mobilizing/sensitizing agents 
have been used as an initial activator 
followed by the cytotoxic drugs (Zeng Z, et al. 
2009; Löwenberg B, et al. 2003), our IL-11R
  targeting peptide, CGRRAGGSC-GG-
D(KLAKLAK)2, both activates the STAT3 and 
simultaneously induces cell death via the 
proapoptotic D(KLAKLAK)2 motif, thus making 
this strategy more specific and potentially 
more effective in targeting of LSCs. 
Consequently, the CGRRAGGSC-GG-
D(KLAKLAK)2 peptide and its derivatives may 
therefore have a dual role in cancer therapy 
as a cell cycle activator and a cell death 
inducer. In accordance with this hypothesis, 
we show that the CGRRAGGSC-GG-
D(KLAKLAK)2 peptide and its myristoylated 
derivative reduced the clonogenic potential of 
patient-derived AML bone marrow cells, while 
they did not have a similar effect on normal 
bone marrow cells at equivalent 
concentrations. Consistently, IL-11R  
expression was also shown in immature 
CD34 positive cell populations derived from 
leukemia patients as demonstrated via flow 
cytometry and cytospin analysis. We 
speculate that the therapeutic targeting of IL-
11R may be capable of eradicating LSCs. 
Further studies are needed to evaluate these 
points. 
 
Taken together, selecting ligand-mimics that 
target different organs in vivo accessible via 
circulation provide an excellent means to 
profile the molecular diversity of a human and 
find clinically relevant targets. Our results 
show that the IL-11R  receptor system 
offers a potential targeting approach for 
therapies in human leukemia and lymphoma. 
 
2. Identification of novel drug candidates 
against leukemia via screening a small 
molecule compound library via the ex vivo 
assay (IV) 
 
The microenvironment has an important role 
in supporting the proliferation and survival of 
cancer cells, thus contributing to disease 
progression. In addition, it has a key role in 
mediating drug efficacy and resistance (Zhou 
J, et al. 2005). Therefore, it is fundamental to 
develop functional screening platforms that 
can assess the therapeutic relevance of drug 
candidates within the appropriate disease 
microenvironment. Although, in vitro 
screening for anti-cancer agents – for 
instance, via the NCI60 cell line panel – has 
been a valuable tool for drug discovery, it 
fails to address the disease 
microenvironment such as host-cancer 
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interactions and the humoral and cellular 
immune system, all of which can significantly 
reduce the drug efficacy in vivo. Markedly, 
the compounds selected via the conventional 
in vitro screening methods are often difficult 
to translate to in vivo settings because the 
activity of a compound is frequently lost or 
significantly reduced. In effect, the co-
existence of the non-malignant host cells (i.e., 
immune, stromal, mesenchymal) and 
leukemia stem cells allows complex 
interactions that are known to affect several 
biological processes, including response to 
therapy, drug resistance, self-tolerance, and 
angiogenesis (Grivennikov SI, et al. 2010; 
Sison EAR and Brown P. 2011; Konopleva M 
and Andreef M. 2007; Kurtova AV, et al. 
2009; Roodhart JML, et al. 2011; Ustun C, et 
al. 2011). Therefore, mouse models are a 
traditional preclinical host to assess anti-
cancer efficacy of a test compound in vivo. 
However, there are several limitations in 
mouse modeling, such as species-specific 
differences, limited recapitulation of de novo 
human tumor development, and differences 
in drug response as compared to humans 
(Cheon DJ and Orsulic C. 2011; Testa U 
2011). For instance, mice have a tendency to 
be more resistant to many anti-cancer 
compounds than patients (Teicher BA. 2009). 
The lack of functional immune system in 
these models may also interfere with the 
outcome, as immune surveillance is known to 
contribute to several aspects of 
tumorigenesis. For instance, certain 
populations of lymphocytes and leukocytes 
play a tumor-supporting role in cancer 
(Grivennikov SI, et al. 2010; Ustun C, et al. 
2011). Consequently, immunocompromised 
mouse models often fail to recapitulate the 
human microenvironment properly, which 
might contribute to the fact that the results 
obtained in xenograft models do not often 
correlate with clinical outcomes. Furthermore, 
high-throughput screening in mice is 
challenging. Therefore, combinatorial 
approaches that use several model systems 
are required to further understand the 
complexity of human cancers (Cheon DJ and 
Orsulic C. 2011). For instance, assays 
involving a removal of the diseased tissue 
from a patient to assess the anti-cancer 
efficacy of a drug in an ex vivo setting prior to 
the actual treatment can be important 
preclinical tools. 
 
In this study, we developed a new functional 
ex vivo screening assay for leukemia in the 
presence of human blood or bone marrow 
under hypoxic conditions. The advantage of 
our assay is that it allows for the identification 
of efficient anti-leukemia agents that are 
functional in the presence of human blood or 
bone marrow. Markedly, during the ex vivo 
assay development we observed that 
leukemic cells deplete oxygen faster than 
normal cells causing a shift in the hemoglobin 
oxygenation state. This shift, detected by 
measuring the optical density at 600 nm 
(OD600) after an appropriate incubation time, 
directly correlated with leukemic cell counts. 
Therefore, we rationalized that this color 
change could be used as an indicator of 
leukemia cell viability and to screen for 
compounds with anti-leukemia activity. 
Notably, the oxygen-dependent absorbance 
spectra of hemoglobin is well known (Zijlstra 
WG, et al. 1991; Hoppe-Seyler F. 1866), but 
to our knowledge, has never before been 
utilized for drug discovery in blood-containing 
culture. Importantly, our assay requires no 
exogenous marker, such an oxygen probe, 
which has previously been used in the in vitro 
culture systems to monitor oxygen 
consumption (Hynes J, et al. 2009, 2006 & 
2003; Arain S, et al. 2005; O’Riordan TC, et 
al. 2000 & 2007). The “Z-factor” – a 
coefficient that is used as a reflective of both 
the signal dynamic range and the data 
variation in the assay related to the signal 
measurements (Zhang JH, et al. 1999) – was 
calculated to be approximately 0.71 for our ex 
vivo assay, which indicates that the results 
are reproducible and accurate. Nevertheless, 
the donor blood specific differences may 
contribute to observed variation in efficacy of 
drug candidates in different blood samples. 
Thus, the best application of the ex vivo 
assay is as a tool for personalizing therapy 
against human leukemia. 
 
Importantly, our ex vivo assay provides new 
means to evaluate drug efficacy in the 
context of bone marrow microenvironment, in 
which drug resistance is often encountered. 
In addition, although AML has its origin in the 
bone marrow, the leukemic cells can also 
circulate in large numbers in the peripheral 
blood and infiltrate many organs, which is 
associated with poorer prognosis (Chang H, 
et al. 2004). This mobility of AML cells may 
resemble that of hematopoietic stem and 
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progenitor cells, which can sustain 
hematopoiesis in extramedullary sites such 
as the spleen and liver (Zhu J, et al. 2007; 
Ghinassi B, et al. 2010). The circulating 
levels of hematopoietic stem and progenitor 
cells also increase in response to stress, 
inflammation and tissue/organ injury 
(Rarajczak MZ, et al. 2010) and elevated 
levels of MSCs have also been detected in 
peripheral blood of cancer patients (Bian Z-Y, 
et al. 2009; Fernandez M, et al. 1997). 
Hematopoietic progenitor cells can be 
intentionally mobilized into circulation by 
using mobilizing agents, such as CXCR4 
inhibitors, which enhance chemotherapy 
resulting in markedly reduced leukemia 
burden and increase in survival (Zeng Z, et al. 
2009). As such, discovery of leukemia drugs 
that are effective in the presence of bone 
marrow as well as blood components is 
equally important. 
 
Notably, blood and bone marrow are 
relatively easy to obtained from humans, and 
thus provide a unique opportunity for the 
development of preclinical ex vivo assays 
mimicking the human microenvironment. The 
ex vivo assay could also provide information 
about the toxicity of the drugs in humans, as 
bone marrow is critically sensitive to many 
anti-cancer agents (Pessina A, et al. 2003). 
In effect, mouse bone marrow is less 
sensitive to many cytotoxic agents as 
compared to human bone marrow, thus 
allowing blood levels in preclinical efficacy 
testing that are not achieved in patients 
(Pessina A, et al. 2003; Erickson-Miller C, et 
al. 1997; Kummar S, et al. 2006; Kurtzberg 
LS, et al. 2007; Masubuchi N, et al. 2004), 
and therefore rendering mouse models 
inadequate in addressing the human bone 
marrow toxicity. In addition, high-throughput 
screening of small molecules in the in vivo 
model is difficult, and thus chemical libraries 
are readily amenable to in vitro selection only. 
Therefore, the ex vivo assay could be used 
as an alternative approach for screening of 
compounds against cancer.  
It is expected that any drug that is not a 
general toxin will likely have varying 
efficacies depending on the patient sample 
tested. This could be due to differences in 
specific molecular abnormalities carried by 
leukemia cells as well as differences in the 
microenvironment (i.e. blood or bone marrow). 
In blood, factors that can be responsible for 
patient-to-patient variability in response 
effects include different concentrations of 
hydrolyzing enzymes, plasma proteins, and 
red blood cells. All these factors can 
significantly reduce drug efficacy, inactivating 
a drug already in the circulation and 
preventing it from reaching the target tissue. 
In principle, testing drug candidates in the 
presence of blood and bone marrow from a 
leukemia patient should facilitate the 
selection of a therapeutic strategy for the 
individual patient. Indeed in the pilot 
experiments, we were able to optimize the ex 
vivo assay for blood samples directly from 
AML patients. However, some primary 
samples contained such a low percentage of 
blasts that they did not efficiently induce the 
color shift to dark red (i.e. deoxygenate 
hemoglobin). However, this obstacle for the 
assay detection could be overcome by 
isolating a portion of the mononuclear cells 
via Ficoll purification and re-implanting them 
to the remaining donor blood or bone marrow. 
Moreover, detection of low blast counts may 
also be possible via utilization of stronger 
hypoxic condition, such as 1% oxygen levels. 
Furthermore, similar feasibility studies with 
human bone marrow aspirates for cell co-
cultures showed promise in our preliminary 
experiments. These results indicate that the 
ex vivo assay introduced here may also be 
adapted for bone marrow samples from 
leukemia patients. Our preliminary data 
suggest that the ex vivo assay could 
potentially be applied for tailoring treatment 
options for each patient, and may facilitate 
rapid testing of the available leukemia drugs 
and new drug candidates, as well as provide 
guidance regarding a treatment selection or 
intensification during the course of therapy. 
Further studies with larger patient sample 
cohorts and with a variety of subtypes are 
needed to study the translational value of the 
ex vivo assay. 
 
To establish that our ex vivo assay could be 
utilized in the drug discovery, we screened a 
small molecule chemical library against 
leukemia cells in the ex vivo assay setting to 
identify small molecule compounds that had 
robust activity in the presence of human 
whole blood.  
 
Notably, the vast majority of the compounds 
identified via the ex vivo assay screening 
were novel, and many were discovered to be 
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structurally identical or similar to the anti-
cancer, anti-inflammation, or anti-microbial 
compounds described in the literature. These 
known mechanisms of the identified 
compounds support the idea that our ex vivo 
assay is primarily selecting compounds that 
have potential therapeutic value.  However, 
due to the presence of several cell types and 
molecules in the blood, the method can in 
principle also select compounds that affect 
the oxygen-carrier function of hemoglobin 
and red blood cells, or some other aspect of 
host blood cells such as inducing an immune 
reaction. For instance, a compound could in 
theory mimic the oxygen binding to 
hemoglobin, thus inhibiting the observed 
color shift even in the presence of viable 
leukemia cells. As a result, some of these 
compounds could be selected as false 
positives. However, the initial small-scale 
analysis with 20 compounds indicates the 
true-positive hit rate is around 90%, 
suggesting that the majority of the 
compounds selected during the screening 
affected leukemia cells directly. In addition, 
the “false positives” could be easily discarded 
early on with the follow up analysis via 
Coulter counter, which specifically detects the 
reduction in WBC counts thus confirming that 
a particular compound is, in fact, a cell 
viability or growth inhibitor. 
 
Markedly, some of the compounds not 
showing any activity in vitro, could also be 
“prodrugs” – agents, which are activated by 
hydrolysis or by biosynthetic reactions, 
whose metabolites contribute to therapeutic 
activity – and therefore, may be valid 
therapeutic agents in the presence of blood. 
Thus, caution must be used when labeling a 
compound as a “false positive” based on the 
in vitro validation, as some of the compounds 
may in reality be “true hits”. The use of the 
Coulter counter system to count the different 
blood cell populations in a co-culture setting 
will thus be more informative than a standard 
cell culture assay as a validation system.  
 
In addition, as an indirect support to our 
hypothesis that our ex vivo assay could 
identify compounds that are stable in blood, 
many selected compounds contained amide 
moieties, which are more stable against 
plasma hydrolysis than are ester moieties in 
the same position (e.g., Breitenlechner CB, et 
al. 2004). Other factors such as steric 
hindrance near a hydrolysable group – which 
results into differential binding of compounds 
to plasma enzymes (e.g., Borthwick AD, et al. 
2003) – the lack of electron-withdrawing 
groups – which increase the positive charge 
on the phosphorous atom and increase the 
rate of hydrolysis (Sawa M, et al. 2002) – and 
the lack of hydrolyzable groups in the 
compounds may have contributed to 
increased plasma stability.  
 
In summary, the ex vivo assay described 
here can select compounds that are able to 
inhibit leukemia cells in complex co-cultures – 
known to induce drug resistance – as well as 
estimate the prospective stability of 
compounds in circulation. Importantly, the ex 
vivo assay demonstrated several key 
advantages as compared to conventional in 
vitro assays as well as animal models 
including (i) partial recapitulation of the 
human leukemia microenvironment, (ii) use of 
native hemoglobin oxygenation status as a 
“built-in” indicator of leukemia cell 
viability/proliferation, (iii) cost-effectiveness, 
(iv) species-specificity, and (v) high-
throughput screening functionality. We 
anticipate that the ex vivo assay can be used 
to identify new drug candidates for leukemia 
that are stable in blood and bone marrow 
microenvironment, and thus potentially have 
a high translational value. In principle, our 
assay could hypothetically be used as a tool 
to predict clinical outcome, as well as 
facilitate customizing safer and more effective 
treatment strategies for each patient, by 
testing available cancer drugs in patient’s 
own blood and bone marrow, and thus 
potentially selecting the most effective 
treatment options for each patient prior to 
administration. Taken together, our ex vivo 
assay provides a novel and unique research 
tool that can be applied to the discovery of 
novel drug candidates against leukemia and 
can function as a clinical tool for 
personalizing cancer therapy. 
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Concluding remarks 
 
Although clinical advancements in the 
systemic therapy of leukemia have been 
made (Ravandi F. 2011; Ravandi F, et al. 
2007), non-specific toxicity and drug 
resistance result in serious long-term side 
effects, and significant relapse and mortality 
rates. Targeted combination therapies to 
specifically and simultaneously block all the 
disease-driving molecular networks in a 
patient are needed to overcome the disease 
and eradicate all the leukemia cells. In 
addition, customizing a therapy for each 
patient must go beyond targeting of 
aberrations intrinsic to leukemia cells and 
predict how cancer microenvironment affects 
drug response. Discovery approaches will 
need to be accordingly directed so that the 
identification of pathologically important 
targets and effective therapeutic agents is 
possible and probable. For example, the 
phage display technology is a well-
established screening tool that can identify 
new clinically relevant ligand-receptor pairs 
both in vitro and in vivo, and provides an 
excellent tool for identification of cancer-
specific targets, toward which drugs can 
subsequently be developed. Similarly, 
screening of small molecule compounds in 
the ex vivo assays provides a superior 
alternative to standard in vitro screening, and 
facilitates the identification of drug candidates 
effective in the presence of human 
components.  
 
The work presented in this thesis has utilized 
both the phage display technology as well as 
the ex vivo screening platform in the 
discovery of potential therapeutic targets 
against leukemia. Specifically, we identified 
and evaluated three new targets for leukemia 
(namely: the invadosome complex, NRP-1, 
and IL-11R), as well as several candidate 
therapeutic agents against leukemia, 
including the inhibitors of the invadosome 
complex, and proapoptotic ligand-mimics 
binging to NRP-1 and IL-11R, as well as 
several new small molecule compounds with 
efficient anti-leukemia activity. In addition, we 
introduce a novel screening method for 
leukemia, in which compound stabilities and 
efficacies can be tested in the presence of 
human blood or bone marrow, therefore 
facilitating the identification of drug 
candidates that may have translational value. 
This assay may also have future applications 
in personalized cancer medicine. 
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